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Introduction. Deep venous thrombosis (DVT) is a common disease which affects 1−2 out of 
1000 people every year. In Slovenia, approximately 3000 people are yearly diagnosed with 
DVT, which makes it an important health problem. Post-thrombotic syndrome (PTS) is a 
chronic complication, which occurs in 20 to 50% of the DVT patients. PTS reduces the quality 
of life and significantly increases healthcare-related costs. 
Pathophysiology of PTS is complicated and not entirely understood; increased venous 
pressure plays the main role and is caused by chronic vein occlusion and retrograde blood 
flow. PTS can be defined as a combination of different symptoms and signs that appear in 
patients with a history of DVT. Several risk factor have been discovered, such as older age, 
higher body mass, more proximal thrombosis, chronic venous insufficiency, recurrent DVT, 
smoking, and subtherapeutic anticoagulation.  
Pathophysiology of arterial atherosclerotic disease and venous thrombosis used to be 
interpreted as two distinct mechanisms, however, a lot of data show a relationship between 
the two in their etiology. A relationship between blood levels of systemic inflammatory 
markers and atherosclerosis is known; inflammatory markers are sometimes designated as 
novel risk factors for cardiovascular disease. The relationship between inflammation and 
venous thrombosis is less understood, however, studies show that inflammatory markers are 
probably important in the pathophysiology of DVT. Some studies also investigated the 
relationship between inflammation and PTS, however, the results are not conclusive. 
Aim. We aimed to investigate different factors related to DVT and PTS: deteriorated vessel 
wall function, inflammatory and fibrinolytic markers, and recanalization. Additionally, we 
evaluated the incidence and forms of PTS among our DVT patients and compared different 
types of treatment. 
Methods. We included 120 consecutive patients treated for DVT in the outpatient clinic of 
the Department of Vascular Disease, University Medical Centre Ljubljana. Inclusion criteria 
were the following: proximal DVT of lower extremities (V. femoralis communis, V. femoralis 
and/or V. poplitea) and age between 35 and 75 years. Patients with active cancer, 
symptomatic arterial disease, diseases, that would significantly influence levels of systemic 
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inflammatory markers, and those unwilling to participate were excluded. Additionally, we 
included a control group of 40 anthropometrically comparable subjects without a history of 
DVT. 
The research was approved by the Republic of Slovenia National Medical Ethics Committee 
(reference number 121/08/14). Written informed consent was obtained from all patients 
before inclusion in the study. 
Patients were invited for a check-up visit at the clinic in the period between 12 and 36 months 
after the DVT diagnosis. A thorough medical history was obtained, focusing on the DVT 
diagnosis and treatment. A clinical examination was performed, specifically searching for 
signs of PTS. Blood for laboratory analyses of the selected systemic inflammatory and 
fibrinolytic markers was collected and blood pressure, body mass and body height measured. 
Properties of the arterial wall were investigated using several techniques (ultrasound 
assessment of endothelial function of the brachial artery, peripheral tonometry, arterial 
stiffness). Patients answered a questionnaire about leg symptoms. The data was organized 
and statistically analysed.  
Results. Median age of the DVT patients was 60.5 years, a majority of them were men (58%) 
and had increased body mass index (28.7 kg/m2). Out of 120 DVT patients, 34% had a Villalta 
score of 5 or more, fulfilling the criteria for PTS. These patients were older and more often 
had recurrent DVT. The most common symptoms and signs of PTS were leg pain, heaviness, 
cramps and swelling.  
At the time of the ultrasound vein examination, the thrombus was still visible in 72% of the 
DVT patients – in 14% the vein was completely occluded, while in 58% it was partially 
occluded. The group of patients who developed PTS had a lower recanalization rate in 
comparison to the group without PTS; complete recanalization was more often seen in 
patients without PTS (6% vs. 29%, p = 0.001). There were no significant differences in the 
presence of reflux between the groups. 
According to the type of treatment, DVT patients were divided into two groups: 77 patients 
were treated with rivaroxaban and 43 with warfarin combined with a low molecular weight 
heparin in the initial period. Even when adjusted for other factors, such as age, patients 
treated with warfarin had an odds ratio of 4.2 for PTS development (p = 0.005) in comparison 
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to the patients treated with rivaroxaban. A great majority of all DVT patients used 
compression therapy at least in the initial period of the treatment. 
We found statistically significant differences in the endothelial function of the brachial artery 
between patients after DVT and the control group in the period 12 to 36 months after the 
acute DVT. Patients after DVT had decreased FMD (0.04 vs. 0.08, p = 0.001) and NMD (0.12 
vs. 0.19, p = 0.001). An increased brachial artery diameter was found in the DVT group. Using 
peripheral arterial tonometry, we found significantly increased augmentation index (AI) and 
augmentation index, adjusted to the heart rate of 75/minute, (AI75) in patients after DVT in 
comparison to the control group (22.0 vs. 6.0, p = 0.004 and 16.0 vs. 1.5, p = 0.001, 
respectively). No significant differences in the endothelial function of the brachial artery and 
arterial stiffness between PTS-positive and PTS-negative patients were found. 
In laboratory blood analyses, we found important differences in the values of CRP, leukocytes, 
D-dimer, PAI-1 and t-PA in patients more than one year after acute DVT in comparison to the 
control group. No significant differences in blood markers between PTS-positive and PTS-
negative patients were found. 
Conclusions. PTS occurs in about 34% of our DVT patients. Patients with PTS have a reduced 
function of lower limbs, therefore PTS prevention and symptom reduction are necessary in 
DVT treatment. Patients who develop PTS had a lower rate of venous recanalization in 
comparison to DVT patients who do not develop PTS; early recanalization is probably 
important. Patients treated with rivaroxaban had a lower incidence of PTS in comparison to 
the patients treated with warfarin, however, larger randomized study would be needed for 
stronger evidence. Patients with DVT assessed 12 to 36 months after the acute DVT had 
increased diameter of the brachial artery, more deteriorated endothelial function and more 
expressed arterial stiffness in comparison to the control group, indicating an association 
between venous disease and arterial wall function. DVT patients had higher levels of 
inflammatory and fibrinolytic markers measured 12 to 36 months after acute DVT in 
comparison to the control group, indicating increased inflammatory and fibrinolytic activity 
years after acute DVT. No significant differences in the arterial wall function and levels of 
systemic inflammatory and fibrinolytic markers between PTS-positive and PTS-negative 







Uvod. Globoka venska tromboza (GVT) je pogosta bolezen, ki prizadane 1-2 na 1000 
prebivalcev letno. V Sloveniji je z GVT vsako leto diagnosticiranih približno 3000 bolnikov, kar 
predstavlja pomemben zdravstveni problem. Potrombotični sindrom (PTS) je kronični zaplet, 
ki se pojavi pri 20-50 % bolnikov z GVT. PTS zmanjša kakovost življenja in poveča z 
zdravljenjem povezane stroške.  
Patofiziologija PTS je zapletena in ne popolnoma raziskana; pomembno vlogo igra povišan 
venski pritisk, ki ga povzroča kronična zapora vene in retrogradni tok krvi. PTS je definirana 
kot kombinacija simptomov in znakov, ki se pojavijo mesece ali leta po akutni GVT. Znanih je 
več dejavnikov tveganja, kot so višja starost, povišana telesna teža, bolj proksimalna 
tromboza, kronična venska insuficienca, ponavljajoča GVT, kajenja in subterapevtska 
antikoagulacija.  
Arterijska aterotrombotična bolezen in venska tromboza sta bili nekoč smatrani kot dve 
popolnoma ločeni bolezni, vendar več raziskav kaže na povezavo v etiologiji. Povezava med 
sistemskimi vnetnimi pokazatelji in aterosklerozo je znana; za vnetne dejavnike se pojavlja 
celo izraz novi dejavniki tveganja za kardiovaskularno bolezen. Povezava vnetja in venske 
bolezni je manj raziskana, vendar študije kažejo na pomembnost vnetnih dejavnikov pri 
patofiziologiji GVT. Prav tako so nekatere študije raziskovale povezavo med sistemskimi 
vnetnimi dejavniki in PTS, vendar so rezulatati zaenkrat večinoma nasprotujoči.  
Cilj. Naš cilj je bil raziskati različne dejavnike, povezane z GVT in PTS: spremembe v funkciji 
žilne stene, plazemske nivoje sistemskih vnetnih in fibrinolitičnih markerjev ter 
rekanalizacijo. Dodatno smo želeli ugotoviti pogostost in oblike PTS med našimi bolniki z 
GVT ter primerjati načine zdravljenja.  
Metode. Vključili smo 120 zaporednih bolnikov, zdravljenih zaradi GVT v Dnevni bolnišnici 
Kliničnega oddelka za žilne bolezni, Univerzitetni klinični center Ljubljana. Vključitvena 
kriterija sta bila: proksimalna GVT spodnjih okončin (V. femoralis communis, V. femoralis 
in/ali V. poplitea) in starost med 35 in 75 let. Izključili smo bolnike z aktivnim malignim 
obolenjem, simptomatsko arterijsko boleznijo, boleznimi, ki bi lahko pomembno vplivale na 
nivoje sistemskih vnetnih markerjev, ter bolnike, ki niso želeli sodelovati. Dodatno smo 
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vključili kontrolno skupino 40 antropometrično podobnih preiskovancev, ki niso nikoli 
preboleli GVT.  
Raziskavo je odobrila Komisija Republike Slovenije za medicinsko etiko (soglasje številka 
121/08/14). Pred vključitvijo v raziskavo so vsi preiskovanci podpisali pisno soglasje. 
Bolniki so bili 12 do 36 mesecev po diagnozi GVT povabljeni na kontrolni pregled. Pregledali 
smo zdravsteno dokumentacijo, se pogovorili z bolniki in naredili klinični pregled, pri čemer 
smo se osredotočili na znake in simptome PTS. Odvzeli smo kri za krvne preiskave sistemskih 
vnetnih in fibrinolitičnih markerjev, izmerili krvni tlak, telesno težo in telesno višino. Z 
različnimi metodami smo merili smo lastnosti arterijske žilne stene (ultrazvočna ocena 
endotelijske funkcije brahialne arterije, periferna tonometrija, togost arterij). Preiskovaci so 
izpolnili vprašalnik o težavah z nogo. Podatke smo organizirali in jih statistično obdelali.  
Rezultati. Mediana starosti bolnikov z GVT je bila 60,5 let, večji del je bilo moških (58 %), v 
povprečju so imeli povišan indeks telesne mase (28,7 kg/m2). Izmed 120 bolnikov po GVT jih 
je 34 % zbralo 5 ali več točk po točkovniku Villalta, s čimer so izpolnjevali kriterije za PTS. 
Bolniki s PTS so bili starejši in so pogosteje imeli ponavljajoče GVT. Najpogostejši simptomi in 
znaki so bili bolečina, teža in krči v nogi ter otekanje noge.  
Ob ultrazvočnem pregledu ven je bil tromb še vedno viden pri 72 % bolnikov z GVT – v 14 % 
je bila vena popolnoma okludirana, medtem ko je bila v 58 % le delno okludirana. Bolniki, ki 
so razvili PTS, so imeli nižjo stopnjo rekanalizacije v primerjavi z bolniki brez PTS; popolna 
rekanalizacija je bila pogostejša pri bolnikih brez PTS (6 % proti 29 %, p=0,001). V prisotnosti 
refluksa statistično pomembnih razlik med skupinama nismo opažali.  
Glede na način zdravljenja smo bolnike razdelili na dve skupini – 77 bolnikov je bilo zdravljenih 
z rivaroksabanom, 43 pa z varfarinom v kombinaciji z nizkomolekularnim heparinom ob 
začetku zdravljenja. Tudi ko smo rezultate vključili v multiplo analizo z ostalimi dejavniki, kot 
je starost, so imeli bolniki zdravljeni z varfarinom 4,2-krat višje obete za razvoj PTS v primerjavi 
z bolniki, zdravljenimi z rivaroksabanom (p=0,006). Velika večina vseh bolnikov je vsaj v 
začetnem obdobju redno uporabljala kompresijsko terapijo. 
Našli smo statistično značilno razliko v endotelijski funkciji brahialne arterije med bolnikih 12 
do 36 mesecev po GVT in kontrolno skupino. Bolniki po GVT so imeli nižjo od pretoka odvisno 
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vazodilatacijo - FMD (0,04 proti 0,08, p=0,001) in od endotelija neodvisno vazodilatacijo - 
NMD (0,12 proti 0,19, p=0,001). Bolniki po GVT so imeli tudi povišan premer brahialne 
arterije. S pomočjo periferne arterijske tonometrije smo izmerili statistično značilno povišan 
augmentacijski indeks (AI) in augmentacijski indeks, prilagojen na frekvenco 75 
utripov/minuto (AI75) pri bolniki po GVT v primerjavi s kontrolno skupino (22,0 proti 6,0, 
p=0,004 ter 16,0 proti 1,5, p=0,001). Med bolniki z in brez PTS pomembnih razlik v endotelijski 
funkciji brahialne arterije ter meritvah periferne tonometrije nismo izmerili.  
Izmerili smo pomembne razlike v laboratorijskih vrednostih CRP, levkocitov, D-dimerja, PAI-1 
in t-PA pri bolnikih več kot eno leto po akutni GVT v primerjavi s kontolno skupino. Med bolniki 
z in brez PTS pomembnih razlik v nivojih sistemskih vnetnih in fibrinolitičnih markerjev nismo 
izmerili.  
Zaključki. PTS se je pojavil pri 34% naših bolnikov z GVT. Bolniki s PTS imajo zmanjšano 
funkcijo nog, zato je pri zdravljenju GVT potrebno preprečevanje in zmanjševanje simptomov 
PTS. Bolniki s PTS so imeli nižjo stopnjo rekanalizacije prizatedih ven v primerjavi z bolniki po 
GVT, ki PTS niso razvili; zgodnja rekanalizacija je verjetno pomembna pri zdravljenju GVT. 
Bolniki, zdravljeni z rivaroksabanom, so imeli nižjo incidenco PTS v primerjavi z bolniki, 
zdravljenimi z varfarinom, vendar bi bila za zanesljiv dokaz potrebna večja randomizirana 
raziskava. Bolniki po GVT so imeli 12 do 36 mesecev po akutni GVT večji premer brahialne 
arterije ter bolj izraženo endotelijsko disfunkcijo in togost arterij v primerjavi s kontrolno 
skupino, kar nakazuje povezavo med vensko boleznijo in funkcijo arterijske žilne stene. Bolniki 
z GVT so imeli v primerjavi s kontrolno skupino 12 do 36 mesecev po akutni GVT višje nivoje 
sistemskih vnetnih in fibrinolitičnih markerjev, kar kaže na povečano vnetno in fibrilnolitično 
aktivnost tudi več kot eno leto po akutni GVT. Pomembnih razlik v lastnostih arterijske žilne 
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1.1 Problem definition 
 
Deep vein thrombosis (DVT) is a chronical vascular disease which most commonly affects deep 
veins of the lower extremities and is often accompanied by local and systemic complications. 
Systemic complications include pulmonary embolism (PE), which usually appears in the acute 
period of the disease and can be fatal, while the most important local complication is the 
post-thrombotic syndrome (PTS). It often follows DVT in the chronic phase and significantly 
lowers the quality of life. PTS leads to other complications, such as chronic vein insufficiency 
[1]. Pathological mechanisms of DVT and especially PTS development are not completely 
understood.  
 
1.2 Deep vein thrombosis 
 
1.2.1 Epidemiology and pathophysiology of deep vein thrombosis 
 
DVT is a common disease with a yearly prevalence of 0.2% among adult population and up to 
25% among hospitalized patients. In Slovenia at least 3000 people are affected by the disease, 
making it an important health problem [2,3]. 
DVT usually affects deep veins of the lower extremities. Formation of a blood thrombus 
occludes the venous lumen, therefore blocking the blood flow. This is caused by a destroyed 
equilibrium among different factors that either provoke or prevent blood coagulation. In 
some cases, a specific risk factor for DVT development is detected, however, many patients 
develop a so called idiopathic or unprovoked DVT, in which the specific cause is unknown. 
Chronic risk factors include malignant disease, previous venous thromboembolisms, chronic 
diseases (nephrotic syndrome, inflammatory bowel disease, myeloproliferative diseases, 
obesity) and thrombophilia – an either genetic or acquired change in blood coagulation, such 
as antithrombin, protein C or protein S deficiency, presence of factor V Leiden and 
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prothrombin gene mutation. Short-term risk factors include trauma, prolonged rest, surgical 
procedures, immobilisation, pregnancy, hormonal contraception use, and long flights [1,4]. 
 
1.2.2 Clinical features and diagnostics of deep vein thrombosis 
 
Clinical features, symptoms and signs of the disease depend on DVT location and size. The 
most common sign is leg swelling, which usually includes foot and calf, while thigh can also 
be affected in iliofemoral DVT. Heaviness and leg tension can be accompanied by leg pain, 
particularly while standing. The calf can be warmer, skin colour can change, and varicose veins 
can become more prominent. Typically, pain at calf compression occurs and Homans sign – 
calf pain during foot dorsiflexion – is positive. Incomplete vein occlusions and small extent 
DVT can result in an asymptomatic disease.  
The diagnostic process begins with DVT probability assessment, for which Wells' criteria can 
be used; it consists of typical patient history and clinical features. If the DVT probability is 
moderate or high, ultrasound vein examination should be performed. The most specific 
ultrasound sign is vein incompressibility, while presence of thrombus and flow obstruction 
are also often seen. Diagnostics of DVT also includes measurement of the D-dimer level; 
presence of DVT can be excluded with high probability, when the D-dimer level is low [5,6].  
Distinction between recurrent DVT and residual thrombus after a previous DVT is sometimes 
difficult; comparison of the imaging results at the time of the suspected recurrence with the 
baseline results at the time of the previous DVT is usually used [7]. Several definitions for 
residual thrombus exist; most often thrombus diameter of > 2 mm during maximal venous 
compression [8,9] or residual vein occlusion of ≥ 40% [10] are used. In our study, we modified 
the method for determining the residual thrombus first described by Prandoni et al [9].  
 
1.2.3 Treatment and complication of deep vein thrombosis 
 
The most important role in the DVT treatment is played by the anticoagulation drugs, which 
can prevent thrombus propagation, local complications, and PE development, as well as 
reduce the risk for recurrent DVT. Until a few years ago, oral vitamin K antagonists (mostly 
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warfarin) were predominantly used, accompanied by low molecular weight heparin (LMWH) 
subcutaneous injections at the beginning of the treatment. In recent years, novel oral 
anticoagulation drugs (NOAC) were introduced. Most commonly used are rivaroxaban and 
apixaban, which directly inhibit factor Xa, and dabigatran, which inhibits thrombin. 
Advantages of NOACs include fast onset of action, less food and drug interaction and more 
stable plasma concentration, which reduces the need for frequent laboratory check-ups. In 
some cases (especially in patients with malignant diseases), LMWH or standard heparin are 
still used [11,12]. Among patients included in our study, either warfarin or rivaroxaban was 
used. 
Duration of the treatment varies with the thrombus location and the presence of DVT risk 
factors. In first isolated unprovoked calf DVT and in DVT with a known reversible risk factor, 
anticoagulation treatment can usually last 3 months. In unprovoked proximal DVT, treatment 
of at least 6 months is required, while cases with a permanent risk factor sometimes require 
long-term anticoagulation treatment. In extensive DVT, thrombolytic treatment is sometimes 
used, while insertion of inferior vena cava filter is required in some patients (particularly 
patients with malignant diseases) [5]. 
The most important acute complication is PE, which develops in up to 50% of untreated DVT 
patients, particularly in cases where the thrombus propagates proximal of the popliteal vein. 
Massive PE can result in death. Chronic complications of DVT include recurrent DVT and 
chronic thromboembolic pulmonary hypertension, however, the most common chronic 
complication of DVT is development of local symptoms and signs, together called post-
thrombotic syndrome [5,13].  
 
1.3 Post-thrombotic syndrome 
 
1.3.1 Epidemiology of post-thrombotic syndrome 
 
Post-thrombotic syndrome is a common chronic complication which develops in 20−50% of 
the DVT patients despite optimal anticoagulation treatment. Severe cases are seen in 5−10% 
of the patients [14]. Most patients develop first signs and symptoms of PTS within several 
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months to years after acute DVT, however, in some cases it develops as late as 10 years after 
the acute event. In 10 years, up to 5% of patients develop leg ulcerations as a consequence 
of PTS [15]. PTS reduces the quality of life and work productivity of the patients, as well as 
significantly increases healthcare-related costs. In the United States and Canada, PTS related 
costs are estimated at thousands of dollars per patient per year and are significantly higher 
in comparison to DVT patients without PTS [15,16]. Some data show that patients with PTS 
can have a lower quality of life then patients with chronic obstructive pulmonary disease, 
diabetes or arthritis, while quality of life of patients with a severe form of PTS can be 
compared to patients with heart failure or cancer [1,17].  
 
1.3.2 Pathophysiology and risk factors of post-thrombotic syndrome 
 
Pathophysiology of PTS is complicated and not yet completely understood. Important role is 
played by increased venous pressure, caused by chronic vein occlusion and retrograde blood 
flow [14,15].  
On DVT onset, newly formed thrombus completely or partially obstructs normal venous blood 
flow. In weeks and months after the acute event, changes in thrombus size, shape and 
constitution occur, gradually enabling venous recanalization. Despite these events, about one 
half of all DVT patients still have thrombus residuals in the affected veins even years after 
acute DVT, causing partial or total vein obstruction. Recanalization rate depends on thrombus 
size and location – more distal is the thrombus location, faster is the recanalization process 
[1].  
Inflammation and slower thrombus resolution lead to chronic vein occlusion and therefore 
damage of the venous valves, resulting in a retrograde blood flow. Incidence of retrograde 
blood flow increases with time and is present in up to one half of all DVT patients one year 
after the acute event. Degree of venous occlusion and thrombus recanalization rate have an 
impact on venous valve function [1]. Blood is pushed from the calves towards the heart by 
muscle contraction during walking, while venous valves prevent retrograde blood flow due to 
gravitation. Venous valve damage diminishes their role, thus enabling retrograde blood flow 
and increasing peripheral venous pressure [15]. 
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Several risk factors for PTS development have already been discovered. A positive correlation 
exists between the incidence of PTS and older age, increased body mass index (BMI), more 
proximal thrombosis and known chronic venous insufficiency. It also seems to be associated 
with recurrent GVT, smoking suboptimal anticoagulation treatment and incomplete 
recanalization. Less certain is the association between PTS development, increased D-dimer, 
type of anticoagulation treatment and inflammatory markers [15]. Studies found no clear 
association with patient gender, presence of thrombophilia, duration of anticoagulation 
treatment, intensity of anticoagulation treatment, and physical activity. [15].  
 
1.3.3 Clinical features and diagnosis of post-thrombotic syndrome 
 
PTS exists in different forms and is defined as a combination of typical symptoms and signs 
that occur in months to years after acute DVT. Most common are leg swelling, leg pain, leg 
heaviness, cramps and pruritus [14]. Symptoms can be permanent or occasional; they usually 
improve with leg elevation or rest and worsen during physical activity. Several signs can be 
discovered with clinical examination – swelling of leg, particularly calf, telangiectasia, 
hyperpigmentation, and redness. Leg ulceration can occur in severe cases, particularly after 
minor injury [1]. 
Several scales can be used to diagnose and categorize PTS. Most common are Villalta scale,  
Ginsberg scale, Brandjes scale and Widmer's classification [15]. Villalta scale (Table 1) includes 
both symptoms and signs of PTS, and has a high correlation with the quality of life of the 
patients [18]. PTS is defined as Villalta score of 5 or more and has three categories. Mild PTS 
is defined as a score between 5 and 9, moderate as a score between 10 and 14, while severe 
PTS is defined as a score of 15 or more. Regardless of the score, any PTS is defined as severe, 




Table 1 - Villalta scale for PTS diagnosis and classification 
Symptoms Signs 
Pain 0      1      2      3 Pretibial oedema 0      1      2      3 
Cramps 0      1      2      3 Skin induration 0      1      2      3 
Heaviness 0      1      2      3 Hyperpigmentation 0      1      2      3 
Paraesthesia 0      1      2      3 Redness 0      1      2      3 
Pruritus 0      1      2      3 Venous ectasia 0      1      2      3 
 Pain during calf compression 0      1      2      3 
Ulcer 0                      3 
 
 
1.3.4 Prevention of post-thrombotic syndrome 
 
The most effective way of preventing PTS is lowering the incidence of DVT. Therefore, 
thromboprophylaxis is recommended in patients with increased risk for DVT. However, about 
one half of all DVT cases are unprovoked, therefore, secondary prevention is warranted [15]. 
This includes treatment with medication, compression, and endovascular therapy.  
Sufficiently long and intensive anticoagulation treatment is recommended in DVT patients, as 
it prevents DVT recurrence, an important risk factor for PTS. In patients treated with vitamin 
K antagonist, international normalized ratio (INR) below recommended level can increase the 
incidence of PTS for 3-times, therefore, adequate INR levels particularly at the beginning of 
the treatment are important in PTS prevention. No differences in the effectiveness in PTS 
prevention among different anticoagulation drugs has been found until now [15]. 
Classic method of PTS prevention is compression therapy, either compression stockings or 
bandages. It lowers the venous pressure and edema, increasing tissue microcirculation [20]. 
Patients use the compression therapy during the day and take them off while sleeping [14]. 
Several studies (Bandjes et al, Prandoni et al) showed lower incidence of PTS in patients using 
compression stockings in comparison to patients not using compression stockings [21]. 
However, the SOX trial (Compression Stockings to Prevent the Post-Thrombotic Syndrome), 
the first large double blind randomized study, showed no difference in Villalta scale between 
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the patients wearing compression stockings after DVT in comparison to the patients wearing 
placebo, as well as no improvement in the quality of life [22]. Therefore, newer guidelines less 
clearly recommend compression therapy as a method of PTS prevention, while maintaining 
their role in symptom reduction in patients after DVT [17]. 
Early thrombus removal leads to a better blood flow in the vein, lowering the venous pressure 
and improving vein valve function. Two older approaches have considerable weaknesses: 
systemic thrombolysis can cause systemic bleeding, while surgical thrombectomy is an  
invasive procedure [15]. To avoid these complications, two newer techniques were 
developed. Catheter directed thrombolysis (CDT) enables delivery of the thrombolytic agent 
along the catheter directly to the location of the thrombus, therefore lowering the incidence 
of systemic bleeding, while at the same time increasing the concentration and prolonging the 
time of action of the thrombolytic agent. Similar is pharmacomechanic CDT (PCDT), where 
mechanical percutaneous thrombus removal is performed along with local thrombolytic drug 
administration. Additionally, balloon angioplasty and stent insertion can be performed 
[13,23]. Guidelines recommend usage of CDT or PCDT in rare cases along with anticoagulant 
treatment. Balloon angioplasty with or without stent insertion is recommended in selected 
patients. Surgical thrombectomy can be performed in very rare cases, when patients are not 
candidates for CDT and PCDT, however, systemic thrombolytic treatment is not 
recommended [15]. 
 
1.3.5 Treatment of post-thrombotic syndrome 
 
Once PTS has already developed, several ways of treatment can be used, however, their effect 
is limited [1].  
Classical PTS treatment includes compression therapy with elastic stockings; although no 
clear benefit has been proven yet, it is recommended in patients with developed PTS, while 
intermittent compression devices are recommended in some cases [17]. Physical activity, 
consisting of muscle strengthening exercises and aerobic activity, probably improves PTS 
symptoms and is therefore recommended in PTS patients who are able to perform it [15,24]. 
Some studies showed some improvement of PTS symptoms with several medications 
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(rutosides, hidrosmin, defibrotide), however, the effect is modest and not researched enough 
[15]. In severe cases of PTS, invasive techniques can be used, including vein bypass, 
endovascular treatment with stent insertion [25–27], venous transposition and others. If 
patients develop ulcers, these have to be treated accordingly; compression, medications, and 
vein valve reconstruction are possible options [15]. 
 
1.4 Characteristics of vessel wall and association with vein thrombosis 
 
Pathophysiology of arterial atherosclerotic disease and venous thrombosis used to be 
explained as two separate mechanisms, however, recent studies show that both diseases 
share similar or same etiologic and pathophysiologic factors, while properties of arterial and 
venous walls are related [28,29].  
Functional and morphological deterioration of the arterial wall is related  to the development 
of cardiovascular disease; they are sometimes used as a prognostic factor for cardiovascular 
events [30]. Several methods for arterial wall assessment have been established; the most 
common is intima-media thickness [31], however, endothelial dysfunction [32] and arterial 
stiffness [33] are also used.  
Intima and medial are inner layers of the arterial wall; their thickness can be measured using 
ultrasound, most commonly in the carotid arteries. Increased intima-media thickness (IMT) is 
an early sign of atherosclerosis; its relationship with atherosclerosis has been extensively 
studied [31,34]. There is also a known relationship between venous thrombosis and increased 
IMT as an early sign of atherosclerosis. In comparison to similar healthy subjects, patients 
with a history of DVT, particularly patients with unprovoked DVT, have an increased IMT, as 
found in several studies [29,35]. 
 
1.4.1 Endothelial dysfunction 
 
It became clear that vessel wall is not just a passive barrier, but rather an active element, 
related to the development of atherosclerosis and cardiovascular disease [36]. Endothelial 
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dysfunction is a systemic deterioration of the inner layer of the vessel wall, which is associated 
to a disbalance between dilative and antithrombotic factors on one side, and constrictive and 
prothrombotic factors on the other side [32]. Changes in the endothelial function develop 
early in the process of atherosclerosis and can be measured before the clinically expressed 
atherosclerosis to which they contribute [37].  
Several techniques for endothelial function measurement have been developed, invasive at 
first and non-invasive later, based on the fact that endothelial dysfunction is a systemic 
process expressed also in more easily accessible peripheral arteries [38]. Celermajer et al. 
described the technique of brachial artery endothelial function measurement, which is still 
used today [39,40]. Important measurements are low flow mediated constriction (L-FMC), 
flow mediated dilation (FMD), and nitroglycerin mediated dilation (NMD). 
Another method of endothelial function measurement is peripheral artery tonometry (PAT) 
or finger plethysmography; like endothelial function of the brachial artery, it measures 
vascular response to the blood flow changes, however, it is measured on a finger, where not 
only large arteries but also microvascular bed play a role. Measurement is easier to perform 
and more automated, reducing the differences between investigators. The result is shown as 
reactive hyperaemia index (RHI), which represents a relationship between flow amplitude 
change on the arm with occluded flow and the opposite arm during and after the occlusion. 
Arterial stiffness is also calculated by the device. Correlation between RHI and FMD is not 
always present, which indicates that different mechanisms play a role [32,38]. 
Direct venous wall function is difficult to measure. There are some known methods, however, 
they are invasive and not easily reproducible [38]. Several studies showed a relationship 
between arterial and venous wall, therefore, arterial wall function has been used as a 
surrogate for venous wall function in some cases. Patients with a history of DVT had 
deteriorated endothelial function of the arteries, as shown in several studies that focused on 
FMD and NMD [41–44]; there are no clear data on PAT [45]. As venous wall deterioration, 
particularly venous valve damage as a result of persistent venous thrombus, is important in 
PTS development, it would be possible that patients with an already deteriorated wall 
function have an increased risk for PTS, if they develop DVT. No published studies investigated 
the relationship between PTS and endothelial function yet. 
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1.4.2 Arterial stiffness 
 
Stiffness represents resistance of the artery to deformation and is determined by different 
components of the arterial wall [46]. The changes in the extracellular matrix and the 
mechanical vessel characteristics, related to the arterial stiffness, are important in the process 
of atherosclerosis. Several studies [47,48] showed a relationship between arterial stiffness 
and the incidence of cardiovascular events [33].  
Different methods can be used to measure arterial stiffness. The golden standard is pulse 
wave velocity (PWV), which represents the speed of pulse wave movement between two 
points. It is usually measured on carotid and femoral artery, however, other peripheral 
arteries can be used, such as index finger as a part of peripheral tonometry. Due to physical 
properties of the vessel, pulse wave travels faster along stiff arteries [33,49]. Pulse wave in 
the aorta consists of the wave moving towards the periphery, caused by the heart 
contraction, and a subsequent return wave, caused by rebound from the peripheral vessels. 
Blood travels faster in stiffer arteries, therefore, the return wave occurs sooner after the 
antegrade wave, and thus a higher pressure increase is seen. Analysis of the shape of the 
pulse wave can be used to assess the stiffness of the artery. Measured increase in the pressure 
caused by the retrograde wave is called augmentation pressure (AP), while its ratio with the 
pulse pressure is called augmentation index (AI). AI depends on the heart rate, therefore a 
more reliable value is AI, adjusted to the heart rate of 75 beats/minute (AI75) [46,49,50].  
Because similar factors and involved in both arterial and venous wall deterioration, changes 
in arterial stiffness could be expected in DVT patients, however, there are no available studies 
to confirm it. Similarly, there are no studies investigating the relationship between arterial 
stiffness and PTS. 
 
1.5 Systemic inflammatory and fibrinolytic markers  
 
Inflammation plays an important role in the pathophysiology of venous thrombosis. It starts 
with the accumulation of neutrophils, which are followed by macrophages. Numerous 
cytokines, chemokines, adhesion molecules and other inflammatory factors together with 
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coagulation factors are involved in thrombus progression, its organisation and recanalization 
[51,52]. Inflammation is probably initiated by thrombin, which triggers production of several 
factors in the vessel wall, such as vascular cell adhesion molecule (VCAM), intercellular 
adhesion molecule (ICAM), and selectins. Inflammatory factors, such as interleukins 6, 8 and 
10 (IL-6, IL-8, IL-10) are also produced [53,54].  
A relationship between atherosclerosis and serum concentration of systemic inflammatory 
markers has been shown in numerous studies; inflammatory markers have even been 
designated as novel risk factors [55,56]. However, the relationship between inflammatory 
markers and venous disease is less established. Some studies also investigated the 
relationship between inflammatory markers and PTS. Studied markers include CRP, IL-6, IL-8, 
IL-10, ICAM and VCAM, among others. The results were mostly inconclusive [57,58]. 
Fibrinolysis is a physiologic process of thrombus resolution; it plays in important role in 
venous recanalization and blood flow improvement. Fibrin degradation is triggered by 
plasmin, which is an active form of plasminogen. Its activation is under the influence of t-PA, 
produced mainly in the endothelial cells. Most of the plasma t-PA molecules are bound to 
PAI-1, which prevents its activity. Several other molecules take part in the complex process of 
fibrinolysis, such as urokinase, factor XII, prekallikrein, high molecular kininogen, antiplasmin, 
and others. The goal of this process is fibrin degradation; one of the degradation products is 
also D-dimer [59]. Several markers have been shown to be associated with DVT and PTS 




2 Purpose and hypotheses 
 
We wanted to investigate factors related to the DVT as well as factors related to the PTS 
among patients with a history of DVT. We were particularly interested in the deterioration of 
vessel wall function, systemic inflammatory response and recanalization.  
We set the following hypotheses:  
1. Patients diagnosed with DVT have deteriorated function of the vessel wall and 
increased levels of systemic inflammatory markers in comparison to the healthy 
controls.  
2. Patients with DVT, who developed PTS, have more deteriorated function of the vessel 
wall and increased levels of systemic inflammatory markers in comparison to the DVT 
patients without PTS. 
We were also interested in the relationship between the venous recanalization rate and the 
presence of the PTS, prevalence and the clinical characteristics of the PTS among our DVT 








3.1 Selection of participants 
 
We included consecutive patients, treated for DVT in the outpatient clinic of Department of 
vascular disease, University medical centre Ljubljana. Inclusion criteria were the following: 
iliofemoral, femoropopliteal or popliteal thrombosis (proximal DVT), and age between 35 and 
75 years. Exclusion criteria were the following: active cancer or cancer associated DVT, 
symptomatic arterial disease and known diseases that would significantly influence levels of 
systemic inflammatory markers. We also excluded patients who were unwilling to participate. 
Additionally, we included a control group consisting of demographically comparable 
individuals without a history of DVT. 
We followed Helsinki declaration, Oviedo convention and Slovenian codex of medical 
deontology. The research was approved by the Republic of Slovenia National Medical Ethics 
Committee (reference number 121/08/14). Written informed consent was obtained from all 
patients before inclusion in the study. 
 
3.2 Study design 
 
The presence and extent of the venous thrombosis was determined by skilled physicians 
based on pre-test probability, D-dimer value and duplex ultrasound. During ultrasound 
examination, a combination of venous non-compressibility, respiratory dependency and 
blood flow assessment during distal compression were used. Ultrasound evaluation has high 
specificity and sensitivity for DVT, including iliofemoral DVT. In case of reduced visibility in the 
iliofemoral region, abdominal probe was used, while in some cases MR or CT venography 
were additionally used.  
Participants were again investigated in the period between 12 to 36 months after acute DVT. 
We reviewed their medical history and performed a thorough examination, focusing on 
symptoms and signs, consistent with PTS. Blood samples were analysed and body height, 
body weight and arterial pressure measured. Ultrasound was used to determine 
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recanalization and reflux in the affected veins. We used several methods to determine 
properties of the arterial wall. Participants answered a questionnaire about leg symptoms - 
Lower extremity functional scale (LEFS) [61].  




3.3.1 Clinical examination 
 
We analysed medical documentation and discussed with patients their medical history, 
treatment of DVT and possible symptoms of PTS. Clinical examination was performed, and 
signs of PTS assessed. Villalta score was used for PTS assessment; symptoms and signs were 
considered to be related to PTS if they occurred or worsened after the acute DVT and if they 
were more expressed in the leg affected by DVT in comparison to the opposite leg. Patients 
with a Villalta score of 5 or more were characterized as PTS-positive, while patients with a 
lower score were characterized as PTS-negative. We used an automatic blood pressure 
monitor to determine the systolic and diastolic blood pressure after 15 minutes of rest. Height 
and weight of the patients were also measured.  
 
3.3.2 Ultrasound examination of lower extremity veins 
 
Characteristics of the deep veins of the lower extremities were investigated using ultrasound 
(Aloka Prosound Alpha, Hitachi Aloka, Tokyo, Japan). The presence of the remaining thrombus 
in the affected vein as well as the presence of reflux were investigated.  
For the measurement of residual thrombus, participants were lying supine with a slightly 
elevated headrest. A 10 MHz probe was used to display the veins in a two-dimensional grey 
scale (B-mode). Each venous segment was also scanned with the help of colour and pulse 
Doppler. We carefully examined deep veins of both legs, in particular the common femoral 
vein (V. femoralis communis) at the saphenofemoral junction, the femoral vein (V. femoralis) 
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2 cm distally to the saphenofemoral junction, and the popliteal vein (V. poplitea) in the mid 
popliteal fossa. The diameters of the veins were measured in the longitudinal plane with the 
ultrasound probe only gently positioned on the skin surface, whereas the vein compressibility 
was measured during maximal compression in the transverse plane. We modified the method 
of Prandoni et al [9]; the compressibility was the main criteria for defining residual thrombus. 
Veins were considered completely recanalized if the diameter of the compressed vein was 
less than 2 mm at the time of full compression. If the vein was not completely recanalized, 
we further divided them into either partially recanalized or occluded. The vein was considered 
occluded when it was completely incompressible and there was no colour signal detected in 
the venous lumen, while it was considered partially recanalized when there was blood flow 
present.  
Venous reflux (i.e. reverse venous flow) was assessed measuring the duration of the 
retrograde blood flow using a 10 MHz probe. We evaluated the reflux at two locations – at 
the level of the common femoral vein proximal to the saphenofemoral junction and at the 
popliteal vein in the mid popliteal fossa. The measurement was taken each time above the 
level of the venous valves. Retrograde flow in the common femoral vein was assessed in 
upright position during Valsalva manoeuvre [62,63]. The patient was leaning against the 
examination table so that the examined leg was relaxed and body weight was carried by the 
opposite leg. The patient was asked to inspire deeply, hold his breath and try to push the 
stomach out like during defecation, without opening the mouth or nose. For the assessment 
of the popliteal reflux, the examining sonographer performed manual compression and rapid 
decompression at the mid-calf by using the hand that was not involved in the scanning [64]. 
Previous studies showed that there was no significant difference between the measurements 
performed using manual or automatic compression-decompression [63]. Initial manual 
compression was performed at the mid-calf level to obtain a visible flow velocity increase, 
followed by rapid relief of the pressure to the calf. The examined venous segment was shown 
in the longitudinal plane. Using colour Doppler, we confirmed that the venous lumen was 
completely filled with a colour signal, thereafter the pulse wave Doppler indicator was placed 
in the middle of the venous lumen. The reflux was considered present if the retrograde flow 
lasted for 1 second or more in duration [65].  
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The overall presence of reflux was defined as the presence of reflux at any of the two 
positions. If a part of the venous segment was occluded, the assessment of reflux was done 
at the vein level where it was feasible.  
Additionally, we included the results of the routine ultrasound examination, performed in the 
most of the patients 12 months after the acute DVT; thrombus was characterized as either 
present or absent at that time.  
 
3.3.3 Ultrasound measurements of the endothelial function 
 
Ultrasound was used to measure the brachial endothelial function according to the current 
guidelines [40]. We included three techniques. The most commonly used is flow-mediated 
dilation (FMD), which measures the change of the artery diameter during the hyperaemia 
following the release of the pressure cuff. Low-flow mediated constriction (L-FMC) measures 
the artery diameter reduction during the cuff occlusion of the brachial artery [66], while 
nitroglycerin mediated dilation (NMD) measures the artery diameter change after the 
sublingual application of nitroglycerin and shows particularly functional capability of the 
smooth muscle cells in the arterial wall [39].  
We used Aloka ultrasound (Hitachi, Japan). Investigation was performed at the room 
temperature of 22−26 °C. Every participant was resting for at least 10 minutes in supine 
position before the measurement and remained in the same position during measurements. 
A sphygmomanometer cuff was placed on the right forearm. Participant's right arm was 
placed in the outright position. We used the ultrasound B-mode to find the brachial artery 
2−15 cm above the cubital fossa and searched for the location with the best longitudinal 
visibility of the artery. After a good image was found, the ultrasound probe was placed in a 
special holder, preserving the same position for the duration of the measurements. We 
measured all diameters in the diastole, which we ensured with the electrocardiogram 
monitoring. Three measurements were always made and the average calculated. The 
diameter was first measured at rest; thereafter, average blood velocity in the middle of the 
artery was measured using the colour Doppler signal at a 68˚ angle. The blood flow was 
calculated from the diameter of the artery and the blood velocity.  
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A compression cuff was inflated to a pressure of 50 mmHg above the systolic pressure. The 
artery diameter and the blood flow were measured again after 4 minutes of occlusion at the 
same manner as at rest. After 4.5 minutes, the cuff was deflated; the blood flow was 
measured 15−20 seconds after the deflation and the artery diameter during the hyperaemia 
45−60 seconds after the deflation, at the same manner as at rest. After a 10-minute rest, 0.4 
mg of nitroglycerine (NTG) were applied sublingually. The artery diameter and the blood flow 
were measured 5 minutes after the application at the same manner as at rest.  
Low-flow mediated vasoconstriction (L-FMC) was determined using the formula: 
       Brachial artery diameter during constriction (mm) – Diameter at rest (mm) 
L-FMC= ----------------------------------------------------------------------------------------------------- 
Diameter at rest (mm) 
 
Flow mediated vasodilation (FMD) was determined using the formula: 
  Brachial artery diameter during hyperaemia (mm) – Diameter at rest (mm) 
FMD = ------------------------------------------------------------------------------------------------------- 
Diameter at rest (mm) 
 
 
Nitroglycerin mediated vasodilation (NMD) was determined using the formula: 
  Brachial artery diameter after NTG (mm) – Diameter at rest (mm) 
NMD = ------------------------------------------------------------------------------------------------------ 
    Diameter at rest (mm) 
 
3.3.4 Peripheral arterial tonometry 
 
PAT was measured using EndoPAT device (Itamar Medical, Israel), which also measures 
arterial stiffness. The anthropometric characteristics were inserted into EndoPAT software, 
including age, weight and blood pressure. The participants were lying in supine position 
throughout the whole process. The sphygmomanometer cuff was placed on the right arm and 
the measuring probes were placed on the index fingers on both hands. After the probes were 
inflated, we performed a testing measurement for one minute, followed by a pulse wave 
amplitude measurement. For the initial five minutes, the pulse waves were measured at rest, 
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thereafter, the sphygmomanometer cuff was inflated for five minutes to 50 mmHg above the 
systolic pressure or at least to 200 mmHg; after deflation, the signal was measured for 
additional five minutes. EndoPAT software automatically calculated reactive hyperaemia 
index (RHI), augmentation index (AI) and augmentation index, normalized to the heart rate of 
75/minute (AI75).  
 
3.3.5 Arterial stiffness 
 
The arterial stiffness was measured using SphygmoCor device (AtCor Medical, Australia), 
additionally to the arterial stiffness measured with EndoPAT device. Participants rested for at 
least 10 minutes before the measurements. During the procedure, participants were lying 
supine and wore no tight clothes or jewellery.  
The anthropometric characteristics were inserted into SphygmoCor software, including age, 
weight, and blood pressure. The detection probe was placed on the site of palpable radial 
pulse in the distal part of the forearm. A recording with a clear signal that was at least 10 
seconds long was obtained; the measurement was performed three times. SphygmoCor 
software calculated augmentation pressure (AP), augmentation index (AI) and augmentation 
index, normalized to the heart rate of 75/minute (AI75).  
An electrocardiogram was constantly recorded. We measured the distance between the 
upper border of the sternum and the measuring position on the forearm and the carotid 
artery. Another 10-second signal was obtained on the carotid and the radial artery as 
described above; the measurement was performed three times. SphygmoCor software 
calculated the pulse wave velocity (PWV) from the distance and time from the systole to the 
pressure change in the peripheral artery.  
 
3.3.6 Laboratory analyses of blood 
 
The blood samples were collected at the time of the check-up between 7 am and 10 am from 
the cubital vein after a rest of at least 15 minutes; time of the venous compression was 
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minimized. The participants were not eating food for at least 12 hours and abstained smoking 
for the same period of time.  
The following analyses were performed: 
- Complete blood count; 
- Biochemical analyses: serum concentration of glucose, potassium, sodium, urea, 
creatinine, total cholesterol, high-density lipoprotein cholesterol (HDL cholesterol), 
low density lipoprotein cholesterol (LDL cholesterol – Friedewald equation) and 
triglycerides;  
- Coagulation analyses:  plasma prothrombin time - international normalized ratio (PT-
INR), fibrinogen and D-dimer;  
- Vitamin: serum 25-(OH)-vitamin D; 
- Additional inflammatory, adhesive and fibrinolytic markers: C reactive protein (CRP), 
interleukin 6, 8 and 10, P-selectin, ICAM-1, t-PA and PAI-1. 
All laboratory analyses were performed in the Laboratory for haemostasis and 
atherothrombosis, Department for Vascular Disease, UKCL, with the exception of serum 25-
(OH)-Vitamin D, which was performed in Clinical institute for clinical chemistry and 
biochemistry, UKCL.  
Blood for complete blood count was collected into vacuum tubes Vacutainer with K-EDTA and 
analysed with an automatic haematology analyser KX-21N (Sysmex, Kobe, Japan). Blood for 
the biochemical analyses was collected into vacuum tubes without an anticoagulant. Serum 
was prepared using a centrifuge for 15 minutes at 2000 g and temperature of 20 ̊ C. The levels 
of serum glucose, potassium, sodium, creatinine, and urea were measured using auto 
analyser Vitros Fusion 5.1 FS (Ortho Clinical Diagnostic, Raritan, USA). The concentration of 
total cholesterol, HDL cholesterol and triglycerides were measured with standard calorimetric 
method using analyser Vitros Fusion 5.1 (Ortho Clinical Diagnostics, Raritan, USA), while LDL 
cholesterol was calculated using the Friedewald equation. Plasma was prepared using a 
centrifuge for 15 minutes at 2000 g and temperature of 15 ˚C. Plasma PT-INR was measured 
using Thromborel S reagent (Siemens, Marburg, Germany). The level of vitamin D was 
measured using the chemiluminescent immunoassay (CLIA) with reagents DiaSorin (DiaSorin, 
Saluggia, Italy).  
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The inflammatory and adhesion markers were mostly measured in serum, while fibrinolytic 
markers were measured in citrate plasma. Blood was prepared using a centrifuge for 20 
minutes at 2000 g and temperature of 22 ˚C; plasma was removed and placed into sterile 
cryovials; they were immediately frozen to -70 ˚C and stored. Before the analyses vials were 
incubated at 37 ˚C for 10 minutes. For serum preparation, blood without an anticoagulant 
was centrifuged for 15 minutes and 2000 g and temperature of 20 ˚C. 
Concentrations of IL-6, IL-8, IL10, P-selectin and CRP were measured using multiplex 
technology (Luminex) on MagPix analyser using R&D Systems reagents (R&D Systems, 
Minneapolis, USA). Concentration of ICAM-1 was measured using ICAM-1 Quantikine ELISA 
(R&D Systems, Minneapolis, USA). 
Plasma t-PA in PAI-1 level was measured using Asserachrom ELISA set (Diagnostica Stago, 
Asnières sur Seine, France). Concentration of D-dimer was measured with 
immunoturbidimetry and Innovance D-dimer reagent on automated coagulation analyser 
CS2100i (Siemens, Marburg, Germany). The concentration of fibrinogen was measured with 




The participants answered a questionnaire about leg symptoms at certain everyday tasks 
(Table 2). The questionnaire was adapted from The Lower Extremity Functional Scale (LEFS) 

















1. Any of your usual work 0 1 2 3 4 
2. Usual hobbies, sport 0 1 2 3 4 
3. Getting into the bath 0 1 2 3 4 
4. Walking between rooms 0 1 2 3 4 
5. Putting on socks 0 1 2 3 4 
6. Squatting 0 1 2 3 4 
7. Lifting groceries from floor 0 1 2 3 4 
8. Light home activities 0 1 2 3 4 
9. Heavy home activities 0 1 2 3 4 
10. Getting into/out of a car 0 1 2 3 4 
11. Walking 500 m 0 1 2 3 4 
12. Walking 2 km 0 1 2 3 4 
13. Climbing 10 steps 0 1 2 3 4 
14. Standing for 1 hour 0 1 2 3 4 
15. Sitting for 1 hour 0 1 2 3 4 
16. Running on even ground 0 1 2 3 4 
17. Running on uneven ground 0 1 2 3 4 
18. Running fast 0 1 2 3 4 
19. Hopping 0 1 2 3 4 
20. Rolling over in bed 0 1 2 3 4 
 
 
3.4 Statistical analysis 
 
The statistical analyses were performed using SPSS program, version 22 (IBM, USA). The 
distribution was analysed using Kolmogorov–Smirnov test. Normally distributed continuous 
variables were presented as averages and standard deviations. Other contiguous variables 
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were presented as median and interquartile range, which was marked in the result tables. 
Groups were compared using t-test and Mann Whitney test, respectively. Categorical 
variables were presented as percentages and groups were compared using chi-square test. In 
some cases, we used univariate and multiple linear and logistic regression models. P value of 





4.1 Characteristics of participants 
 
We included 120 patients who were treated for DVT and fulfilled inclusion in exclusion 
criteria. The median age was 60.5 years, patients were mostly male (58%) and on average had 
an elevated BMI (28.7 kg/m2). The control group included 40 participants demographically 
similar to DVT patients, however, without a history of DVT. Patients with DVT had higher BMI 
in comparison to the control group, which is expected, as increased body weight is a risk factor 
for DVT development. There were no other important differences between DVT patients and 
the control group, with an exception of systolic blood pressure (Table 3). 
 
Table 3 - Demographic characteristics and cardiovascular risk factors 
 DVT patients  
(n = 120) 
Control group  
(n = 40) 
p 
Age (years)* 60.5 (51-68.75) 57.5 (49-63.75) 0.313 
Male gender 69 (58%) 22 (55%) 0.782 
Body weight (kg)* 86 (78-97) 77 (64-89) 0.005 
Body height (cm) 173.2 (±10.1) 172.3 (±8.9) 0.619 
BMI (kg/m2)* 28.7 (25.4-31.6) 26.0 (22.2-29.3) 0.004 
Systolic blood pressure (mmHg) 137.2 (±18.1) 127.1 (±17.3) 0.002 
Diastolic blood pressure (mmHg)* 81 (72-90) 79.5 (71-85) 0.297 
Arterial hypertension 49 (41%) 12 (30%) 0.222 
Hyperlipidaemia 46 (38%) 12 (30%) 0.342 
Current smoker 21 (18%) 7 (18%) 1.000 
Past or current smoker 60 (50%) 21 (53%) 0.784 
Pack years* 2 (0-20) 5 (0-15) 0.941 
Prescribed medication 71 (59%) 19 (48%) 0.198 
DVT, deep venous thrombosis; BMI, body mass index,  
* median, interquartile range, Mann-Whitney test 
 48 
Our patients had a left sided DVT in 60% of cases. Etiology of DVT was unclear in 61% of cases, 
which were considered unprovoked or idiopathic DVT. Pulmonary embolism (PE) occurred in 
8% of DVT patients; 8% of the patients had a recurrent DVT (Table 4). Patients were treated 
with rivaroxaban in 64% of cases, while 36% of patients were treated with warfarin, together 
with LMWH in the initial period. A large majority of patients daily used compression therapy 
(92%); compression stockings were more often used than compression bandages; median 
time of compression therapy was 1.5 years (Table 5).  
 
Table 4 - Clinical characteristics of deep venous thrombosis 
 n = 120 
Left sided  72 (60%) 
Thrombus location  
     iliofemoral 29 (24%) 
     femoropopliteal 55 (46%) 
     popliteal (with/without calf involvement) 36 (30%) 
Etiology  
     primary 73 (61%) 
     provoked 47 (39%) 
Pulmonary embolism 10 (8%) 
Recurrent thrombosis 9 (8%) 
Time from symptom onset to treatment 
(days)* 
7 (4-23)  
Time from acute DVT to follow-up 
(months)* 
22 (17-28) 
DVT, deep venous thrombosis;  




Table 5 - Treatment of deep venous thrombosis 
 n = 120 
Anticoagulation  
     rivaroxaban 77 (64%) 
     warfarin (+LMWH) 43 (36%) 
Duration of treatment (months)* 6  
Compression  
     daily 110 (92%) 
     occasional 10 (8%) 
Duration of compression (years)* 1.5 (0.5-2.0) 
Type of compression  
     stockings 94 (78%) 
     bandages 26 (22%) 
LMWH, low molecular weight heparin;  
* median, interquartile range, Mann-Whitney test 
 
4.2 Post-thrombotic syndrome 
 
The most common symptoms of PTS among our patients included leg pain, heaviness and 
cramps, while the most common signs were leg swelling and venous ectasia. In most of the 
cases, symptoms were present in a mild form. Median of Villalta score was 3, while 34% of 
patients had a score of 5 or more, fulfilling the criteria for PTS. Increased circumference of 




Table 6 - Signs and symptoms of post-thrombotic syndrome 
 Absent Mild Moderate Severe 
Symptoms     
     Pain 67 (56%) 42 (35%) 11 (9%) - 
     Cramps 75 (63%) 37 (31%) 8 (7%) - 
     Heaviness 66 (55%) 35 (29%) 18 (15%) 1 (1%) 
     Paraesthesia 96 (80%) 18 (15%) 6 (5%) - 
     Pruritus 105 (88%) 13 (11%) 2 (2%) - 
Signs     
     Pretibial edema 56 (47%) 58 (48%) 6 (5%) - 
     Skin induration 109 (91%) 8 (7%) 3 (3%) - 
     Hyperpigmentation 101 (84%) 17 (14%) 2 (2%) - 
     Redness 80 (67%) 40 (33%) - - 
     Venous ectasia 52 (43%) 57 (48%) 11 (9%) - 
     Pain  during calf compression 117 (98%) 3 (3%) - - 
     Ulcer 99 (99%) 1 (1%) - - 
     
Average score - symptoms* 2 (0-3)    
Average score - signs* 2 (1-3)    
Average Villalta score* 3 (2-5.75)    
Villalta score of 5 or more 41 (34%)    









Figure 2 - Number of DVT patients with different Villalta scores 
 
Patients after DVT were divided into two groups according to the presence of PTS; these two 
groups were compared. Patients who developed PTS were significantly older (62.5 vs. 56.8 
years, p = 0.007). There were no other statistically significant differences in anthropometric 


















































Table 7 - Demographic characteristics and risk factors for cardiovascular disease - 
comparison between PTS-positive and PTS-negative patients 
 PTS-positive  
(n = 41) 
PTS-negative  
(n = 79) 
p 
Number of patients 41 79  
Age (years) 62.5 (±9.6) 56.8 (±11.4) 0.007 
Male gender 20 (49%) 49 (62%) 0.164 
Body weight (kg)* 90 (78-99) 85 (74-97) 0.422 
Body height (cm) 172.5 (±8.5) 173.6 (±10.9) 0.571 
BMI (kg/m2)* 28.7 (25.8-33.5) 28.7 (24.9-31.1) 0.364 
Systolic blood pressure (mmHg) 140.6 (±18.1) 135.4 (±17.9) 0.136 
Diastolic blood pressure (mmHg) 82.3 (±11.1) 81.7 (±12.8) 0.796 
Arterial hypertension 22 (54%) 27 (34%) 0.062 
Hyperlipidaemia 14 (34%) 32 (41%) 0.630 
Current smoker 7 (17%) 14 (18%) 1.000 
Past or current smoker 19 (46%) 41 (52%) 0.700 
Pack years* 0 (0-25) 3 (0-20) 0.603 
PTS, post-thrombotic syndrome; BMI, body mass index 
*median, interquartile range, Mann-Whitney U test 
 
Comparison of DVT characteristics between PTS-positive and PTS-negative patients showed 
no important differences, with the exception of more common recurrent DVT in the PTS-
positive group. However, PTS-positive patients had been more often treated with warfarin 
and less often with rivaroxaban, when compared to the PTS-negative group. Patients using 
compression stockings instead of compression bandages had lower incidence of PTS; even 
when adjusted for patient’s age and duration of compression in a multiple logistic regression 
model, the difference was still statistically significant. Patients with PTS had a significantly 




Table 8 - Deep venous thrombosis characteristics - comparison between PTS-positive and 
PTS-negative patients 
 PTS-positive 
(n = 41) 
PTS-negative  
(n = 79) 
p 
Left sided 22 (54%) 50 (63%) 0.307 
Thrombus location    
     iliofemoral 12 (29%) 17 (22%) 0.628 
     femoral 18 (44%) 37 (47%)  
     Popliteal (with/without calf involvement) 11 (27%) 25 (32%)  
Pulmonary embolism 4 (10%) 6 (8%) 0.685 
Etiology    
     primary 27 (66%) 46 (58%) 0.417 
     provoked 14 (34%) 33 (42%)  
Recurrent DVT 6 (15%) 3 (4%) 0.033 
Time from symptom onset to treatment 
(days)* 
8.5 (3-19) 7 (4.5-30) 0.634 
Time from DVT diagnosis to PTS assessment 
(months)* 
23 (18.5-27) 22 (17-29) 0.646 
Treatment    
     rivaroxaban 20 (49%) 57 (72%) 0.011 
     warfarin 21 (51%) 22 (28%)  
Compression usage    
     daily 36 (88%) 74 (94%) 0.270 
     occasionally 5 (12%) 5 (6%)  
Type of compression    
     stockings 27 (66%) 67 (85%) 0.017 
     bandages 14 (34%) 12 (15%)  
    
Lower extremity functional scale (%)* 84 (68-91) 99 (95-100) ˂0.001 
PTS, post-thrombotic syndrome; DVT, deep venous thrombosis 
*median, interquartile range, Mann-Whitney U test, **not available for all participants 
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Additionally, we included several factors that were associated with PTS in a multiple logistic 
regression model and found age, recanalization, warfarin treatment and compression 
bandage use (instead of compression stockings) were associated with PTS even when 
adjusted for other measured factors (Table 9). 
 
Table 9 - Factors associated with PTS (logistic regression) 
 Univariate Multiple 
 OR (95% CI) p OR (95% CI) p 
Age (years) 1.05 (1.01-1.09) 0.009 1.05 (1.00-1.09) 0.041 
Recurrent DVT 4.34 (1.03-18.4) 0.046 3.11 (0.62-15.5) 0.167 
Absent recanalisation 8.18 (2.32-28.8) 0.001 14.5 (3.07-68.7) 0.001 
Compression bandages 2.90 (1.19-7.06) 0.019 5.67 (1.76-18.3) 0.004 
Warfarin treatment 2.72 (1.24-5.95) 0.013 3.08 (1.23-7.69) 0.016 
OR, odds ratio; CI, confidence interval; DVT, deep venous thrombosis 
 
4.3 Vein recanalization and other morphological characteristics 
 
We evaluated deep veins of the lower extremities using ultrasound. Remaining thrombus was 
present in 72%, out of which 14% of veins were completely obstructed, while 58% of veins 
were only partially obstructed. PTS-positive group had a statistically significant lower 
recanalization rate in comparison to the PTS-negative group. No differences in the presence 




Table 10 - Ultrasound characteristics of the lower limb - comparison between PTS-positive 
and PTS-negative patients 
 PTS-positive  
(n = 41) 
PTS-negative 
(n = 79) 
p 
VFC diameter (mm) 12,6 (±3,0) 12,5 (±2,7) 0,897 
VF diameter (mm) 7,2 (±1,7) 7,8 (±2,1) 0,112 
VP diameter (mm)  7,3 (±2,4) 7,7 (±2,5) 0,414 
    
Recanalization    
     total 3 (7%) 31 (39%) ˂0,001 
     partial 26 (63%) 43 (54%)  
     absent 12 (29%) 5 (6%)  
    
Reflux 18 (44%) 26 (33%) 0,236 
VFC, common femoral vein, VF, femoral vein; VP, popliteal vein 
 
4.4 Treatment of deep vein thrombosis 
 
Based on the type of DVT treatment, we divided patients into two groups: 77 patients had 
been treated with rivaroxaban, while 43 patients had been treated with warfarin. Patients 
treated with rivaroxaban had a lower incidence of PTS and a lower Villalta score (Table 11).  
Variables that were associated with PTS were included into univariate and multiple logistic 
regression models. Even when adjusted for other measured factors, patients treated with 
warfarin had an odds ratio of 4.2 when compared to the patients treated with rivaroxaban 




Table 11 - Demographic characteristics and DVT characteristics – comparison between 
patients treated with rivaroxaban and warfarin 
 Rivaroxaban  
(n = 77) 
Warfarin  
(n = 43) 
p 
Age (years)* 61 (50-68) 59 (51-70) 0.793 
Male gender 46 (60%) 23 (53%) 0.506 
BMI (kg/m2)* 28,7 (25.6-32.0) 28,7 (24.6-31.6) 0.867 
Systolic pressure (mmHg) 137,6 (±17.8) 136,5 (±18.8) 0.771 
Current smoker 12 (16%) 9 (21%) 0.460 
    
Thrombus location    
     iliofemoral 20 (26%) 9 (21%) 0.650 
     femoral 36 (47%) 19 (44%)  
     popliteal  21 (27%) 15 (35%)  
Pulmonary embolism 5 (6%) 5 (12%) 0.329 
Etiology of DVT    
     primary 47 (61%) 26 (60%) 0.674 
     provoked 30 (39%) 17 (40%)  
Recurrent DVT 6 (8%) 3 (7%) 0.871 
Time from symptom onset to 
treatment (days)* 
10 (5-30) 7 (4-14) 0.057 
Time from DVT diagnosis to PTS 
assessment (months)* 
20 (16-24) 28 (23-32) <0.001 
Villalta score* 3,0 (1.5-5) 4,0 (3-7) 0.004 
Post-thrombotic syndrome 20 (26%) 21 (49%) 0.011 
*median, interquartile range, Mann-Whitney U test 
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Table 12 - Association between anticoagulation treatment and PTS (logistic regression) 
 Univariate Multiple 
 OR (95% CI) p OR (95% CI) p 
Age (years) 1.05 (1.01-1.09) 0.009 1.05 (1.01-1.10) 0.017 
Recurrent DVT 4.34 (1.03-18.4) 0.046 3.43 (0.73-16.1) 0.118 
Time from symptom onset to 
treatment (days) 
1.00 (0.99-1.02) 0.659 1.01 (0.99-1.03) 0.225 
Time from diagnosis to PTS 
assessment (months) 
1.01 (0.96-1.07) 0.683 0.97 (0.90-1.04) 0.345 
Warfarin treatment 2.72 (1.24-5.95) 0.013 4.24 (1.55-11.6) 0.005 
OR, odds ratio; CI, confidence interval; DVT, deep venous thrombosis 
 
4.5 Functional properties of the arterial wall 
 
The functional properties of the arterial wall were investigated using several methods, 
including measuring endothelial function of the brachial artery. We found significant 
differences in all three measured parameters of endothelial dysfunction (L-FMC, FMD and 
NMD) between DVT patients and the control group. Patients after DVT also had larger 
diameter of the brachial artery (Table 13). There were no significant differences in the 





Table 13 - Ultrasound measurement of endothelial function of the brachial artery – 
comparison between DVT patients and controls 
 DVT patients  
(n = 120) 
Control group  
(n = 40) 
p 
Brachial artery diameter – at rest 
(mm) 
4.8 (±0.9) 4.4 (±0.7) 0.017 
    
Blood flow    
     at rest (ml/min)* 175 (99-255) 155 (90-219) 0.394 
     during compression (ml/min)* 56 (30-80) 42 (21-70) 0.209 
     after dilatation (ml/min)* 558 (349-912) 556 (395-815) 0.930 
     after GTN  (ml/min)* 130 (70-269) 126 (67-254) 0.578 
    
L-FMC* -0.02 (-0.04-0.00) 0.00 (-0.02-0.03) 0.003 
FMD* 0.04 (0.01-0.07) 0.08 (0.04-0.11) ˂0.001 
NMD* 0.12 (0.09-0.18) 0.19 (0.10-0.25) 0.001 
DVT, patients with deep venous thrombosis; GTN, glyceryl trinitrate; L-FMC, low-flow mediated constriction; 
FMD, flow mediated dilation; NMD, nitroglycerine mediated dilation 




Table 14 - Ultrasound measurement of endothelial function of the brachial artery – 
comparison between PTS-positive and PTS-negative patients 
 PTS-positive  
(n = 41) 
PTS-negative  
(n = 79) 
p 
Brachial artery diameter – at rest 
(mm) 
4.9 (±0,9) 4,7 (±0,8) 0.217 
    
Blood flow    
     at rest (ml/min)* 202 (116-268) 170 (95-255) 0.173 
     during compression (ml/min)* 59 (37-91) 51 (29-74) 0.168 
     after dilatation (ml/min)* 608 (329-947) 496 (349-912) 0.537 
     after GTN  (ml/min)* 147 (80-256) 126 (66-275) 0.650 






FMD* 0.03 (0.01-0.07) 0.04 (0.01-0.07) 0.555 
NMD* 0.12 (0.08-0.18) 0.12 (0.09-0.17) 0.729 
Diameter at dilatation/constriction* 0.04 (0.02-0.07) 0.07 (0.04-0.10) 0.002 
PTS, post-thrombotic syndrome; GTN, glyceryl trinitrate; L-FMC, low-flow mediated constriction; FMD, flow 
mediated dilation; NMD, nitroglycerin mediated dilation 
*median, interquartile range, Mann-Whitney U test 
 
The endothelial function on the microcirculation level and arterial stiffness was measured 
with the EndoPAT device. We found a significantly higher augmentation index among DVT 
patients, when compared to the control group, while there were no differences in RHI (Table 





Table 15 - Endothelial function of microcirculation and arterial stiffness, measured with 
EndoPAT device – comparison between DVT patients and controls 
 DVT patients  
(n = 100) 
Control group  
(n = 40) 
p 
RHI* 1.88 (1.57-2.51) 1.96 (1.61-2.36) 0.775 
AI* 22 (9-30) 6.0 (-5.0-22.8) 0.004 
AI75* 16 (7.5-27) 1.5 (-8.5-13.8) 0.001 
DVT, deep venous thrombosis; RHI, reactive hyperaemia index; AI, augmentation index; AI75, augmentation 
index normalized to heart rate of 75/min  
*median, interquartile range, Mann-Whitney U test 
 
Table 16 - Endothelial function of microcirculation and arterial stiffness, measured with 
EndoPAT device – comparison between PTS-positive and PTS-negative patients 
 PTS-positive  
(n = 34) 
PTS-negative  
(n = 66) 
p 
RHI* 2.09 (1.69-2.61) 1.81 (1.50-2.47) 0.080 
AI* 21.0 (11.8-30.0) 21.0 (2.3-31.0) 0.570 
AI75* 14.5 (8-27) 16.5 (-4.3-28.3) 0.605 
PTS, post-thrombotic syndrome; RHI, reactive hyperaemia index; AI, augmentation index; AI75, augmentation 
index normalized to heart rate of 75/min  
*median, interquartile range, Mann-Whitney U test 
 
Additionally, we used SphygmoCor device to measure the stiffness of the arterial wall. A 
tendency of increased stiffness was seen in DVT patients when compared to the control 
group, however, differences were not statistically significant (Table 17). There were no 




Table 17 - Arterial stiffness measurements – comparison between DVT patients and 
controls 
 DVT patients  
(n = 100) 
Controls  
(n = 40) 
p 
AP 11.7 (±7.4) 8.6 (±6.5) 0.019 
AI 26.1 (±12.6) 22.5 (±15.4) 0.160 
AI75* 25.7 (15.3-31.6) 19.5 (9.1-28.5) 0.091 
PWV* 8.5 (7.9-9.4) 8.3 (7.6-9.1) 0.218 
DVT, deep venous thrombosis; AP, augmentation pressure; AI, augmentation index; AI75, augmentation index 
normalised to heart rate of 75/min; PWV, pulse wave velocity 
* median, interquartile range, Mann-Whitney U test 
 
Table 18 - Arterial stiffness measurements – comparison between PTS-positive and PTS-
negative patients 
 PTS-positive  
(n = 34) 
PTS-negative  
(n = 66) 
p 
AP 12.5 (±7.9) 11.3 (±7.1) 0.442 
AI 27.3 (±12.4) 25.4 (±12.7) 0.476 
AI75* 27.2 (14.6-31.8) 25.0 (13.3-31.5) 0.457 
PWV* 8.5 (8.0-9.4) 8.4 (7.9-9.5) 0.690 
PTS, post-thrombotic syndrome; AP, augmentation pressure; AI, augmentation index; AI75, augmentation 
index normalised to heart rate of 75/min; PWV, pulse wave velocity 
* median, interquartile range, Mann-Whitney U test 
 
4.6 Systemic markers and other laboratory analyses 
 
We found an increased level of leukocytes among patients after DVT, which indicates slightly 
elevated inflammatory activity (Table 19). No differences in basic laboratory markers between 
PTS-positive and PTS-negative patients were found (Table 20).  
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Table 19 - Results of basic laboratory tests – comparison between DVT patients and 
control group 
 DVT patients  
(n = 120) 
Control group  
(n = 40) 
p 
Glucose (mmol/L)* 5.5 (4.9-5.9) 5.2 (4.8-5.6) 0.104 
Urea (mmol/L)* 5.7 (4.8-6.4) 5.5 (4.9-7.1) 0.391 
Potassium (mmol/L)* 4.5 (4.3-4.8) 4.6 (4.4-4.8) 0.724 
Sodium (mmol/L)* 142 (140-143) 140 (138-142) 0.012 
Creatinine (μmol/L) 78.8 (±16.6) 75.7  (±14.5) 0.302 
GFR (ml/min/1,73m2)* 76 (64-88) 79 (65-90) 0.707 
Total cholesterol (mmol/L) 5.6 (±1.3) 5.4 (±1.0) 0.338 
HDL cholesterol (mmol/L)* 1.4 (1.2-1.7) 1.3 (1.1-1.9) 0.956 
Non-HDL cholesterol (mmol/L) 4.0 (±1.3) 3.8 (±0.9) 0.406 
LDL cholesterol (mmol/L) 3.2 (±1.1) 3.2 (±0.9) 0.958 
Triglycerides (mmol/L)* 1.4 (1.0-2.1) 1.2 (0.8-1.5) 0.011 
Leukocytes (109/L)* 5.9 (5.0-7.4) 5.3 (4.5-6.2) 0.001 
Erythrocytes (1012/L)* 4.8 (4.5-5.1) 4.9 (4.4-5.2) 0.713 
Haemoglobin (g/L)* 143 (136-151) 144 (129-151) 0.608 
MCV (fL)* 90 (87-93) 88 (85-92) 0.104 
Thrombocytes (109/L)* 214 (179-252) 214 (189-243) 0.860 
Prothrombin time* 0.93 (0.87-1.01) 0.90 (0.85-0.98) 0.137 
INR* 1.0 (1.0-1.1) 1.1 (1.0-1.1) 0.283 
Fibrinogen (g/L)* 2.90 (2.60-3.30) 2.85 (2.40-3.18) 0.223 
Vitamin D (nmol/L)* 43 (29-57) 47 (34-59) 0.330 
DVT, deep venous thrombosis; GFR, glomerular filtration rate; HDL, high-density lipoprotein; LDL, low-density 
lipoprotein; MCV, mean cell volume; INR, international normalized ratio 




Table 20 - Results of basic laboratory tests – comparison between PTS-positive and PTS-
negative patients 
 PTS-positive  
(n = 41) 
PTS-negative  
(n = 79) 
p 
Glucose (mmol/L)* 5.5 (5.0-6.3) 5.3 (4.8-5.9) 0.157 
Urea (mmol/L)* 5.7 (±1.2) 5.8 (±1.6) 0.816 
Potassium (mmol/L)* 4.5 (4.2-4.7) 4.6 (4.4-4.9) 0.029 
Sodium (mmol/L)* 143 (140-144) 142 (141-143) 0.714 
Creatinine (μmol/L) 74.6 (64.2-87.6) 78.6  (67.7-87.9) 0.442 
GFR (ml/min/1,73m2)* 73 (64-87) 78 (66-89) 0.450 
Total cholesterol (mmol/L) 5.5 (4.6-6.5) 5.5 (4.5-6.5) 0.933 
HDL cholesterol (mmol/L)* 1.4 (1.2-1.8) 1.4 (1.1-1.6) 0.189 
Non-HDL cholesterol (mmol/L) 3.9 (±1.3) 4.1 (±1.2) 0.411 
LDL cholesterol (mmol/L) 3.2 (±1.2) 3.3 (±1.1) 0.757 
Triglycerides (mmol/L)* 1.3 (1.0-2.0) 1.5 (1.0-2.1) 0.356 
Leukocytes (109/L)* 5.7 (5.0-7.4) 6.0 (5.1-7.4) 0.599 
Erythrocytes (1012/L)* 4.7 (±0.4) 4.8 (±0.5) 0.098 
Haemoglobin (g/L)* 141 (135-150) 146 (136-152) 0.253 
MCV (fL)* 89 (88-93) 90 (86-93) 0.701 
Thrombocytes (109/L)* 208 (±60) 222 (±60) 0.230 
PT* 0.91 (0.88-0.99) 0.94 (0.86-1.02) 0.767 
INR* 1.0 (1.0-1.1) 1.0 (1.0-1.1) 0.780 
Fibrinogen (g/L)* 2.8 (2.6-3.2) 3.0 (2.6-3.3) 0.531 
Vitamin D (nmol/L)* 41 (27-51) 44 (29-60) 0.562 
PTS, post-thrombotic syndrome; GFR, glomerular filtration rate; HDL, high-density lipoprotein; LDL, low-
density lipoprotein; MCV, mean cell volume, PT, prothrombin time; INR, international normalized ratio 
*median, interquartile range, Mann-Whitney U test 
 
Serum levels of systemic inflammatory and fibrinolytic markers were compared between 
the groups. We found increased CRP, D-dimer, PAI-1 in t-PA in DVT patients, which indicates 
an elevated inflammatory and fibrinolytic activity even more than one year after the acute 
DVT (Table 21).  
 64 
We found no differences in systemic markers between PTS-positive and PTS-negative 
patients (Table 22).  
 
Table 21 - Measurements of systemic inflammatory, adhesion and fibrinolytic markers – 
comparison between DVT patients and control group 
 DVT patients  
(n = 119) 
Control group  
(n = 40) 
p 
IL-6 (ng/L)* 12.4 (10.5-16.3) 13.1 (9.7-16.2) 0.998 
IL-8 (ng/L)* 32.8 (25.8-45.4) 36.4 (26.1-43.3) 0.915 
IL-10 (ng/L)* 9.1 (8.0-23.7) 21.4 (8.2-24.6) 0.127 
hsCRP (mg/L)* 0.97 (0.63-1.32) 0.74 (0.35-1.00) 0.007 
P-selectin (μg/L)* 44.3 (35.3-56.4) 45.4 (33.5-59.5) 1.000 
ICAM-1 (μg/L)* 319 (215-585) 509  (237-760) 0.103 
D-dimer (μg/L)* 440 (290-840) 305 (180-408) <0.001 
t-PA antigen (ng/mL)* 11.4 (9.1-13.5) 8.7 (6.9-11.9) 0.003 
PAI-1 antigen (ng/mL)* 17.8 (12.2-22.7) 14.4 (9.4-17.9) 0.031 
DVT, deep venous thrombosis; IL, interleukin; ICAM, intercellular adhesion molecule; hsCRP, high-sensitivity C 
reactive protein; t-PA, tissue plasminogen activator; PAI, plasminogen activator inhibitor 




Table 22 - Measurements of systemic inflammatory, adhesion and fibrinolytic markers – 
comparison between PTS-positive and PTS-negative patients 
 PTS-positive  
(n = 40) 
PTS-negative  
(n = 79) 
p 
IL-6 (ng/L)* 12.3 (10.4-15.4) 12.4 (10.5-16.6) 0.996 
IL-8 (ng/L)* 36.9 (27.8-45.2) 30.3 (25.1-50.7) 0.599 
IL-10 (ng/L)* 9.5 (8.0-23.7) 9.1 (8.0-23.7) 0.987 
P-selectin (μg/L)* 42.7 (32.2-45.1) 44.6 (37.3-59.3) 0.328 
ICAM-1 (μg/L)* 365 (238-644) 310 (206-570) 0.335 
hsCRP (mg/L)* 0.91 (0.67-1.31) 0.98 (0.63-1.32) 0.926 
D-dimer (μg/L)* 430 (290-1205) 490 (290-820) 0.989 
t-PA antigen (ng/mL) 11.9 (±3.6) 11.1 (±3.9) 0.319 
PAI-1 antigen (ng/mL)* 17.9 (12.1-22.5) 16.9 (12.2-22.7) 0.811 
PTS, post-thrombotic syndrome; IL, interleukin; ICAM, intercellular adhesion molecule; hsCRP, high-sensitivity 
C reactive protein; t-PA, tissue plasminogen activator; PAI, plasminogen activator inhibitor 







Post-thrombotic syndrome is a common complication of DVT with long-lasting symptoms 
which can significantly reduce the quality of life; its pathophysiology is not yet completely 
understood. Our research included 120 patients with DVT and a control group of 40 
demographically similar subjects without a history of DVT. We looked for symptoms and signs 
of PTS, assessed deep veins using ultrasound, analysed treatment of DVT and measured 
functional properties of the arterial wall and blood levels of several systemic inflammatory 
and fibrinolytic markers.  
 
5.1 Participants and post-thrombotic syndrome 
 
A control group of subjects similar to the DVT group but without a history of DVT was selected; 
they were of similar age and gender and had a similar presence of risk factors for 
cardiovascular disease, such as arterial hypertension, smoking, and hyperlipidaemia. A similar 
percentage of subjects in both groups received prescribed medications. Patients with DVT 
had a slightly higher BMI, which is expected, as higher weight is a risk factor for DVT.  
DVT appears in both genders; its incidence increases with age, so that it is up to five times 
higher between 70 and 80 years of age as it is between 50 and 60 years of age [2]. We included 
only patients aged between 35 and 75 years in order to exclude most of the patients with 
advanced atherosclerosis and keep the sample as homogeneous as possible. The average age 
was 60.5 years, 58% of the patients were male, which is comparable to the literature, given 
that we had an upper age limit. There was no clear reason for DVT development in 61% of 
patients, which were therefore considered unprovoked/idiopathic. This is a high percentage 
in comparison to the data from other studies [67]. However, about 20% of all DVT are cancer-
related, according to the data; we did not include this type of patients, which explains the 
proportionally higher percentage of idiopathic DVT cases.  
PTS appears in 20−50% of DVT patients as a chronic complication and can take years to 
develop [15]. Our patients were evaluated for PTS presence between 12 and 36 months after 
acute DVT; 34% of them had a Villalta score of 5 or more, fulfilling the criteria for PTS. Villalta 
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scale includes several signs and symptoms that are not pathognomonic for PTS, but appear in 
other conditions, such as chronic vein insufficiency; this can cause misinterpretation of the 
results to some extent. However, we can see from the results of our study, that while 
symptoms and signs of PTS do sometimes also occur in the control group, the likelihood is by 
far greater in patients after DVT. Villalta scale is the most common tool used in PTS studies 
and is recommended by International Society on Thrombosis and Haemostasis as a standard 
for PTS diagnosis for research purposes [19].  
Patients with PTS were older than PTS-negative patients (62.5 vs. 56.8 years, p = 0.007), which 
is in line with the data from other studies. Other characteristics, such as increased BMI and 
smoking, are known to be related to PTS, however, this was not seen in our study. We also 
found no significant correlation between the incidence of PTS and the location of the 
thrombus, while most studies show a higher incidence of PTS in patients with a more proximal 
DVT [15]. However, we only included patients with a proximal DVT and excluded distal (calf) 
DVT, therefore, the difference between more proximal and more distal thrombosis was less 
obvious. We confirmed a higher incidence of PTS in patients with recurrent DVT, which was 
also seen in other studies.  
The most frequent symptoms of PTS among our patients were leg pain and heaviness, cramps 
and paraesthesia, while the most common signs were leg swelling and venous ectasia. A 
smaller percentage of patients developed moderate (15%) or severe (3%) form of PTS. This 
can be attributed to the fact, that patients were examined in the period between 1 to 3 years 
after the acute DVT, while severe forms can develop after several years in patients with 
initially mild PTS [1]. A limited follow up time therefore probably underestimated the long 
term prevalence of moderate and severe forms of PTS. However, the total number of PTS 
patients would not increase significantly with a longer follow-up time, as a large majority 
(about 90%) of PTS is already seen after one year [68]. Even when including both PTS-positive 
and PTS-negative patients, symptoms are present in a significantly higher percentage of 
patients in comparison to the control group. This indicates the negative effect of DVT on the 
quality of life, even when symptoms and signs do not fulfil the criteria for PTS. 
When assessing the results of this study, it is important to appreciate that it only included 
patients treated for DVT as outpatients, thus excluding most of the patients with reduced 
mobility and extensive thromboembolic disease. This also partially lowered the measured 
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incidence of severe forms of PTS, which could develop in these type of patients, as well as 
reduced the differences between average PTS-positive and PTS-negative patients. As already 
mentioned, patients aged over 75 years were also excluded. 
We used a questionnaire to assess functionality of the legs in PTS patients in comparison to 
the PTS-negative DVT patients. We found that PTS patients have significantly reduced lower 
extremity functionality, which means typical everyday activities, such as sitting, standing, and 
walking are affected. As such difficulties can significantly lower the quality of life, PTS 
prevention and symptom relief is an important part of DVT treatment. 
 
5.2 Vein recanalization and other morphological characteristics 
 
We used ultrasound to evaluate deep veins of the lower extremities. We found a relationship 
between efficient recanalization and a lower incidence of PTS. Patients who developed PTS 
had a lower degree of recanalization of the affected veins. This was measured as a part of this 
research between 12 and 36 months after the acute DVT, as well as observed in the data of 
the routine ultrasound check-up, performed in most of the patients treated for DVT in our 
clinic about 12 months after the acute event.  
Virchow triad plays an important role in DVT development; it includes prothrombotic blood 
features, deteriorated blood flow and damaged vascular endothelium [69]. Thrombus 
reorganisation is a natural process with a dynamic equilibrium between thrombus lysis and 
its propagation. The equilibrium is in favour of thrombolysis in most of the cases, which results 
in a re-establishment of the venous lumen and a blood flow improvement [70]. The 
fragmentation of the thrombus starts at the periphery, forming clefts and breaking the 
thrombus into smaller pieces, consequently softening the central part and eliminating the 
thrombus [71]. Improvement of the blood flow can be seen already several weeks after the 
acute DVT using ultrasound [72]. Thrombus load is reduced by 50% in the first three months, 
however, even three years after the diagnosis, some residual thrombus can still be seen in 
one half of the patients. [1,73]. Pathophysiology of recanalization is complex; the most 
important role, together with procoagulation activity, is probably played by endogenous 
fibrinolysis [74,75]. Thrombus residuals in the affected vein several months and years after 
the acute DVT are associated with a higher incidence of venous reflux, while early 
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recanalization improves venous valve function and ensures antegrade blood flow [76,77]. 
Residual thrombus and vein wall damage are also risk factors for recurrent DVT. [8,78]. 
Patients with a more proximal DVT have a lower degree of recanalization, which is also a 
group of patients, who have a higher incidence of PTS.  
Plenty data on recanalization after DVT are available, however, there are not many studies 
about the relationship between recanalization and PTS. Deterioration of the venous wall, 
particularly venous valve damage, is probably important in PTS development, together with 
increased venous blood pressure. Insufficient recanalization, which causes both venous valve 
damage and increased venous blood pressure, is therefore likely to be associated with PTS, 
as indicated also by the results of our study. This is in line with the results of Prandoni et al., 
who showed a higher incidence of changes in the veins (such as remaining thrombus and vein 
valve dysfunction) in patients with PTS in comparison to the PTS-negative patients [79]. A 
lower incidence of PTS in the patients with a better recanalization rate was also observed by 
Tick et al [80].  
We also evaluated the presence of a retrograde blood flow (reflux). Reflux was present in 
more than one third of the DVT patients, however, we found no differences between PTS-
positive and PTS-negative patients, unlike the research of Prandoni et al [79]. 
As remaining thrombus in the affected veins is associated with PTS, probably as a 
consequence of chronic venous wall damage and increased venous pressure, early 
recanalization might be important in DVT treatment.  
 
5.3 Treatment of deep vein thrombosis and post-thrombotic syndrome 
 
Although anticoagulation treatment probably plays an important role in PTS development, 
little is known about the effects of different anticoagulants, especially NOACs, on PTS; the 
optimal treatment for PTS prevention is still unknown. A study comparing different durations 
of anticoagulation found no difference in the incidence of PTS between patients treated with 
vitamin K antagonists for 6  weeks or 6 months [81]. It seems that sufficient anticoagulation 
in the initial acute period is more important in PTS prevention than the duration of the 
treatment. In treatment with vitamin K antagonists, sub-therapeutic anticoagulation, 
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especially in the first few weeks, is associated with an up to 3 times higher incidence of PTS 
development later in the chronic phase of the disease [82,83]. A meta-analysis of five 
randomised studies found a smaller incidence of PTS in the patients treated with a long-term 
low-molecular weight heparin alone in comparison to the patients receiving the standard 
treatment with warfarin [84]. This could be attributed to a less stable anticoagulation in the 
treatment with vitamin K antagonist. The importance of initial anticoagulation period is also 
indicated by the results of the study of Kahn et al., which showed that the presence of 
symptoms and signs of  venous disease as early as four weeks after acute DVT is associated 
with later PTS development [85]. Subtherapeutic anticoagulation treatment could maintain 
thrombin production, thus promoting coagulation, reducing natural thrombus lysis and 
causing venous wall damage, which could lead to PTS development in the long-term [86]. It 
has been speculated that NOACs, with their stable pharmacodynamics and rapid onset, could 
lower the incidence of PTS in comparison to vitamin K antagonists [87,88]. However, only one 
available study compared the prevalence of PTS between patients treated with rivaroxaban 
and LMWH/warfarin; the study of Cheung et al. included 336 patients randomized for DVT 
treatment. It found that treatment with rivaroxaban is associated with a lower rate of PTS, 
however, results were not statistically significant [89]. 
Our study includes patients from the period before DOAK availability as well as patients from 
the period when rivaroxaban was predominantly used for DVT treatment. Among our 100 
patients, 61 were treated with rivaroxaban, while 39 were treated with warfarin, overlapping 
with dalteparin in the initial period of 5−7 days (or until INR reached 2.0 to 3.0 for two 
consecutive days) after which dalteparin was discontinued. Even though patients were not 
randomized, there were no anthropometric differences between the groups treated with 
different regimens, as well as no significant differences in other measured factors. As 
rivaroxaban was only recently introduced, there was a longer average period between acute 
DVT and PTS assessment in patients treated with warfarin. We found lower Villalta score and 
lower incidence of PTS in the group of patients treated with rivaroxaban, which was 
statistically significant. Even when adjusted for other measured factors that could affect PTS 
in a multiple regression model, including time from acute DVT to PTS assessment, patients 
treated with warfarin had an odds ratio of 4.2 for the presence of PTS in comparison to the 
patients treated with rivaroxaban.  
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There are probably several reasons for this finding, if confirmed by other studies. Rivaroxaban 
might have more expressed anticoagulation activity, while stimulation of endogenic 
fibrinolysis might also be important in the recanalization of occluded veins. There are no 
clinical data on the thrombolytic activity of NOAC, including rivaroxaban. An experimental 
study indicated that rivaroxaban improves patency of occluded veins and decreases 
inflammation in a mouse model [90], while another study suggested that rivaroxaban causes 
downregulation of pro-inflammatory genes [91]. As inflammation promotes coagulation and 
inhibits endogenic fibrinolysis, it is possible that rivaroxaban with its anti-inflammatory effect 
stimulates fibrinolysis, which can result in more efficient recanalization, as was shown by 
Prandoni et al [92]. However, differences in the recanalization rate were not statistically 
significant in our patients.  
NOACs became very popular in the recent years due to lower incidence of bleeding, less 
interactions with other drugs and food, reduced need for constant laboratory monitoring [93] 
and lower long-term costs of treatment [94]. Decreased incidence of PTS would be another 
advantage of PTS, however, this was a small study and for stronger evidence a larger 
randomised trial would be needed.  
In addition to anticoagulation, thrombolysis can be used for DVT treatment in some cases, 
particularly with extensive DVT [17,95]. A meta-analysis of 17 studies with 1103 included 
subjects showed that patients treated with thrombolysis had better venous patency and 
higher rate of recanalization in comparison to patients treated with anticoagulation only [96]. 
However, an important disadvantage of thrombolysis is an increased risk of bleeding. In 
recent years, the focus is on CDT and PCDT, instead of systemic thrombolysis; using these 
techniques, the thrombolytic agent is delivered to the location of the thrombus, therefore 
reducing systemic side effects. Several small studies showed CDT could better preserve 
venous patency after DVT in comparison to standard anticoagulation [13,97]. Based on results 
of our and other studies that showed better recanalization is associated with lower incidence 
of PTS, thrombolysis might be useful in reducing the incidence of PTS in some patients. A 
randomized ATTRACT trial that included 692 patients was recently finished; results indicate 
that pharmacomechanical PCT might lower the rate of moderate and severe forms of PTS, 
however, without lowering the total incidence of PTS [98]. Some small trials also showed 
promising results of venous stent placement in patients with established PTS, improving the 
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patency of insufficiently recanalized veins [25–27]. Intervention treatment might be useful in 
prevention of more severe forms of PTS in patients with extensive DVT, where such 
development could be expected, however, it is probably not recommended to be used on a 
large scale [99]. 
Additionally, we collected data about compression usage. Compression was daily used for at 
least 3 months by as many as 95% of DVT patients included in the study, while others used it 
occasionally. They used compression stockings more often than compression bandages. Our 
patients who used compression stockings had lower incidence of PTS, compared to patients 
who used compression bandages, which was unrelated to patient’s age or compression 
duration. This might be because bandages are harder to use and are therefore more often 
incorrectly or insufficiently worn. Until recently, compression therapy was recommended as 
an extremely important part of the DVT treatment, which could reduce the incidence of PTS. 
However, a large randomised trial found no significant difference in PTS in comparison to 
patients using a placebo [22]. Newer guidelines do not specifically recommend compression 
as a way of PTS prevention, however, it is still recommended for reduction of symptoms in 
the initial period of DVT treatment as well as symptoms of PTS if they occur [17].  
 
5.4 Measurements of the arterial wall function 
 
We measured properties of the vessel wall in both DVT patients and the control group using 
different techniques. As directly measuring of the venous wall function is complicated, 
invasive and not well reproducible, we used arterial wall function instead. Several studies 
showed an association between arterial and venous wall function [38]. We excluded patients 
with symptomatic arterial disease as well as patients above 75 years old, therefore reducing 
other factors that affect arterial wall function. Asymptomatic arterial disease could also 
influence arterial function, however, DVT patients and the control group were 
anthropometrically similar. Therefore, the presence of significant differences in 
atherosclerosis is probably less likely unless it is associated with venous disease, which would 
confirm our hypothesis. The difference in the arterial wall function between PTS-negative and 
PTS-positive patients could also be affected by age, as PTS-positive patients are older, which 
is also a risk factor for more expressed atherosclerosis. For more reliable results, a regression 
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models that included age could be used, however, there were no differences in the arterial 
wall function between PTS-positive and PTS-negative patients even without adjusting the 
results for age, therefore, the usage of regression models was not needed. 
Despite demographically similar groups, we found more expressed deterioration of the 
arterial wall (endothelial dysfunction and arterial stiffness) in DVT patients when compared 
to the control group; this indicates that an association between venous and arterial disease 
exists. Prandoni et al. found more expressed arterial plaques in the carotid arteries of the 
patients with a history of DVT [28]. This finding is in line with several other studies that 
showed an association between atherosclerosis and venous thromboembolic disease 
[35,41,100,101]. However, a large study on 13000 subjects following them for 12 years found 
no increased risk for DVT in the patients with an increased intima-media thickness of the 
carotid artery [102]. Similarly, Tromso study followed subject for 15 years and found no 
association between increased intima-media thickness and DVT, while finding increased risk 
for myocardial infarction in patients with a larger intima-media thickness [103]. The same 
study found increased incidence of DVT in patients with a family history of myocardial 
infarction [104], as it was also seen in Hunt 2 study [105]. A 20-year population-based cohort 
study based on Danish medical databases showed a significantly increased long term risk of 
arterial cardiovascular event in patients with a history of venous thromboembolism [106]. 
The diameter of the brachial artery was about 10% larger in DVT patients in comparison to 
the control group. Increased peripheral artery diameter is associated with atherosclerosis and 
a higher risk for cardiovascular diseases, according to some studies [107,108], indicating that 
subjects with DVT might have more expressed predisposition for atherosclerosis in 
comparison to the general population. The study of Poredoš et al. found increased diameter 
of carotid and femoral artery in DVT patients, while finding no differences in the brachial 
artery, contrary to our results [109]. We found no differences in the diameter of the brachial 
artery between PTS-positive and PTS-negative patients.  
We used three methods (FMD, NMD and L-FMC) to measure the endothelial function of the 
brachial artery, which is one of the early signs of preclinical atherosclerosis. The difference in 
L-FMC was minimal, while there was an important difference in FMD and NMD; the results 
showed a more expressed endothelial dysfunction in DVT patients in comparison to the 
control group. The patients with DVT had deteriorated endothelium-dependent and 
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independent dilation of brachial artery, indicating that patients with DVT have functional 
changes of the arterial wall, which might be the cause and the pathogenic mechanism of the 
high prevalence of atherosclerotic arterial lesions in patients with DVT. Therefore, endothelial 
dysfunction is most probably a systemic disorder that simultaneously affects the functional 
capability of arterial and venous wall and suggests that a common pathways contribute to the 
atherogenesis, as well as the venous thrombus formation. Several other studies had similar 
results [41–44], however, these studies included only patients with unprovoked DVT, while 
we included DVT patients regardless of the etiology, with the exception of patients with a 
cancer-associated DVT, who were excluded. We also compared patients with and without PTS 
and found no differences in the endothelial function of the brachial artery between the 
groups.  
Peripheral tonometry was performed using EndoPAT device. Unlike the measurements of the 
endothelial function of the brachial artery, PAT is largely automated and less operator 
dependent. It focuses on the function of the microcirculation; its pathological results are 
related to atherosclerosis [110,111], however, data on the relationship between the 
microcirculation and venous disease is scarce. We found an important difference in AI and 
AI75 between the DVT patients and the control group; these indexes describe the arterial 
stiffness, indicating again a relationship between arterial and venous system. This finding 
confirmed that patients with venous thrombosis have an increased stiffness of conduit 
peripheral arteries, which represents a risk factor for the development of atherosclerosis and 
might also be associated with the functional incapability of the venous system, which 
stimulates thrombus formation. There was no difference between the groups in RHI, which 
represents the difference in the blood flow through the microcirculation at the time of the 
hyperaemia, indicating that the microcirculation might not be affected in DVT patients, in 
contrast to the macrocirculation. However, study of Suzuki et al showed a higher incidence of 
DVT after a hip or knee surgery in the patients with a lower RHI in comparison to the patients 
with a high RHI [45]. Different findings are probably partially related to the differences in 
studied groups. Our study included patients with provoked and unprovoked DVT, whereas 
Suzuki et al included only patients with provoked DVT after orthopedic surgery. Furthermore, 
our patients were studied in the period between one to three years after the acute phase of 
DVT, whereas in their study, the measurements were performed at the time of the surgery.  
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We found no differences in any of the EndoPAT measurements between PTS-positive and 
PTS-negative patients.  
Arterial stiffness was additionally assessed using the SphygmoCor device. Several studies 
showed an association between arterial stiffness and atherosclerosis, leading to 
cardiovascular disease [47–49]. Aykan et al. compared arterial stiffness between DVT patients 
and control group, finding an increased heart-ankle index in DVT patients on a small sample 
[112], however, no reliable data have been published yet. We found elevated levels of all 
three augmentation indexes in patients after DVT, however, the difference was not 
statistically significant. As measurements with SphygmoCor are less automated, the lack of 
significant differences between the groups can be partially contributed to the low sensibility 
of the device and large differences between measurements. We found no differences in 
arterial stiffness between PTS-positive and PTS-negative patients. 
The result of our study show their might be an association between the function of the arterial 
wall and deep venous thrombosis. It is indicated by the increased diameter of the brachial 
artery, a more deteriorated endothelial function and increased arterial stiffness, measured 
with peripheral tonometry. On the other hand, we found no differences in the arterial wall 
properties between PTS-positive and PTS-negative patients. This can be partially due to 
limited accuracy of the techniques, however, it indicates that the arterial wall deterioration 
is probably not very important in the development of PTS.  
Relationship between preclinical atherosclerosis and DVT seen in this and other studies 
indicates the importance for DVT prevention in patients with a high risk for atherosclerotic 
cardiovascular disease, as well as prevention of arterial cardiovascular events in patients with 
a history of venous thromboembolic disease, as suggested by Prandoni et al [113]. 
 
5.5 Systemic inflammatory markers and other laboratory analyses of blood 
 
Inflammation is an important factor in the pathogenesis of DVT. Vein wall damage causes an 
inflammatory response, triggering promotion and organization of the thrombus, which causes 
changes of the venous wall. The number of neutrophils in the wall increases first, followed by 
macrophages. The inflammatory response depends on the equilibrium between the pro-
 77 
inflammatory and the anti-inflammatory factors [51]. Inflammation promotes the synthesis 
of the procoagulant factors and reduces the production of the anticoagulant factors, as well 
as increases the expression of the tissue factor on the endothelial cells [114]. Several 
molecules take part in this process, such as cytokines, chemokines and adhesion molecules. 
An important role is played by thrombin, which increases expression of intracellular adhesion 
molecules (ICAM), vascular cell adhesion molecules (VCAM) and selectins [54]; these increase 
the inflow of the inflammatory cells, therefore promoting inflammation [53]. The venous wall 
excretes inflammatory markers, such as interleukin 6, 8 and 10, tumour necrotising factor and 
others [115]. Inflammation is also involved in the thrombus resolution, following the acute 
DVT phase. Changes in the venous wall which increase the risk for PTS occur, such as vein 
valve damage, causing retrograde blood flow and increased intravenous pressure. 
While a lot is known about the association between arterial thromboembolic disease and 
increased levels of different inflammatory markers, studies also showed an association 
between venous thromboembolic disease and different serum markers of inflammation and 
thrombolysis [52,116]. Some studies also found an association between inflammatory 
markers and PTS, however, results are partially unclear and more studies are needed 
[58,115,117]. Some investigators even suggested that thrombosis is in some cases an immune 
response to an infection, which might explain a large number of unprovoked (idiopathic) DVT 
in the elderly population; a term immunothrombosis is sometimes used [118,119].  
Our study evaluated serum levels of several inflammatory markers, adhesion molecules and 
fibrinolytic markers and compared them between DVT patients and the control group. We 
chose to include markers which might be associated to venous disease according to the 
previously published studies. We found statistically significant differences in C-reactive 
protein, D-dimer, plasminogen activator inhibitor 1 (PAI 1), and tissue plasminogen activator 
(t-PA) in patients with DVT in comparison to the control group, while there were no 
differences in the levels of interleukin 6, 8 and 10, P-selectin, and ICAM1. We compared the 
levels of the same markers between PTS-positive and PTS-negative patients and found no 
significant differences between the groups. It is important to stress that blood sample for this 
analysis was taken 1−3 years after the acute DVT, unlike most of the other studies. If we 
measured levels of serum markers immediately after the acute DVT, differences between the 
groups would have probably been more expressed than they are in the chronic phase. 
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Interleukin 6 (IL-6) has an important role in the synthesis of the acute phase proteins in the 
liver, attraction of the inflammatory cells into the vascular wall, activation of the tissue factor 
and also in the chronic inflammation. Several studies investigated the levels of IL-6 during the 
acute and the chronic phase of DVT [57]. Ježovnik et al. showed significantly increased levels 
of IL-6 in DVT patients during the acute phase in comparison to the control group, however, 
levels normalized shortly after the acute phase and were no longer elevated in the chronic 
phase [120]. Studies also measured IL-6 levels in PTS patients. Shabklo et al. [115] and 
Rabinovich et al. [53] showed increased levels of IL-6 in the acute phase of DVT in patients, 
who later developed PTS, however, these values normalized in the chronic phase. This is in 
line with the results of our research, which only measured levels in the chronic phase 
(between 1 to 3 years after the acute DVT) and found no differences among the groups.  
Interleukin 8 (IL-8) is another pro-inflammatory cytokine which is associated with thrombosis 
according to some studies. Henke et al. showed on an animal model that IL-8 application 
increases the proinflammatory action at the thrombus location and promotes the 
revascularisation [121]. Ježovnik et al. showed significantly higher levels of IL-8 in DVT 
patients in the acute phase in comparison to the control group [120]. While one study found 
increased levels of IL-6 in PTS-positive in comparison to the PTS-negative patients [122], most 
of the studies, including our, found no statistically significant differences between the groups 
[57].  
Interleukin 10 (IL-10) is, contrary to IL-6 and IL-8, an anti-inflammatory cytokine, which 
reduces leukocyte adhesion and activation as well as tissue factor expression [123]. Downing 
et al. showed on an animal model that IL-10 application reduces inflammation and has an 
antithrombotic effect on the vessel wall [124]. Some studies described an association 
between the levels of IL-10 and DVT [120] as well as PTS [58], however, other studies found 
no significant association [115]. Our study investigated levels of IL-10 in patients with an 
already developed PTS and found no differences between PTS-positive and PTS-negative 
patients.  Patients with DVT had lower levels of IL-10 in comparison to the control group, 
however, it was not statistically significant. 
C reactive protein (CRP) is one of the most commonly measured blood markers in general and 
is usually used as an inflammation and infection marker. Elevated levels of high sensitivity 
CRP (hsCRP) are associated with arterial atherosclerosis [125]. However, prediction value of 
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CRP for DVT is questionable – two large studies found no association [126,127]. Some studies 
found increased levels of CRP in patients with a history of DVT in comparison to the healthy 
population [120,128]. Studies found no association between increased values of CRP at the 
acute DVT phase and the incidence of PTS afterwards [57]. One study showed increased CRP 
levels in PTS patients in comparison to DVT patients in the chronic phase without PTS [129], 
however, most of the studies found no association [53]. We found slightly higher values of 
CRP in DVT patients between 1 to 3 years after acute DVT in comparison to the control group 
without the history of DVT. This indicates the inflammation process might continue in the 
chronic phase of DVT. We found no differences between PTS-positive and PTS-negative 
patients.  
P-selectin is one of the adhesion molecules which is located on thrombocytes and endothelial 
cells; it is involved in leukocyte adhesion to the vessel wall and thrombocyte activation 
[51,130]. Several studies found an association between increased levels of P-selectin and DVT 
[131]. Smith et al. even suggested P-selectin as a possible marker for DVT with a higher 
specificity than D-dimer [132], however, it was never used on a large scale. We found no 
differences in P-selectin between DVT patients and the control group, probably because 
samples were collected long after the acute phase of DVT. Studies have not found any 
relationship between P-selectin and PTS yet [129], which is in line with our results. 
Intercellular adhesion molecule 1 (ICAM-1) is a transmembrane protein involved in the 
adhesion of leukocytes on the endothelium; its expression depends on several inflammatory 
cytokines and thrombin [133]. Rabinovich et al. found higher levels of ICAM-1 both one month 
and six months after the acute DVT in patients who later developed PTS in comparison to the 
DVT patients who did not develop PTS; they presented it as a marker, most associated with 
the development of PTS [53]. However, a smaller study found no association between PTS 
and ICAM-1 [129]. Similarly, we found no statistically significant differences among the groups 
in our study. 
D-dimer is a product of fibrin degradation; it is the most common blood marker in venous 
thromboembolic disease, as values of D-dimer usually increase during thromboembolic 
disease. Increased levels are associated with coagulation and fibrinolysis activation [134]. 
Increased level of D-dimer predicts increased risk for a recurrent DVT in patients after the first 
DVT [135]. Patients included in our study were treated with anticoagulation for an average 
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time of 6 months; D-dimer levels, measured between 12 and 36 months after the acute DVT 
were elevated in DVT patients in comparison to the control group without a history of DVT. 
This is in line with the study of Gremmel et al., which found that D-dimer levels decline during 
anticoagulation treatment and slightly grow again after anticoagulation treatments stops 
[130]. However, age also affects the level of D-dimer to some extent. Several studies 
evaluated the association between D-dimer and PTS [57]. Bouman et al. measured increased 
levels of D-dimer in PTS patients in comparison to PTS-negative patients [60]; similarly, the 
study of Roberts et al. found higher levels of D-dimer in PTS-positive patients, however, the 
difference was not statistically significant if values were adjusted for age and other factors 
[136]. The study of Sartori et al. also found no association with PTS [137], which is in line with 
our results. 
Tissue plasminogen activator (t-PA) activates plasminogen and triggers the process of 
thrombus degradation called thrombolysis; its synthetic analogue can be used as a 
therapeutic thrombolytic agent [138]. Bouman et al. found increased levels of t-PA in DVT 
patients in comparison to the general population [129], which was also seen in the results of 
our study. As higher levels of t-PA are also a marker of endothelial activation [37], this results 
indicate there might be increased endothelial activation in DVT patients even up to 1−3 years 
after the acute DVT. We found no statistically significant differences in the levels of t-PA 
between PTS-positive and PTS-negative patients, which is in line with the results of Bouman 
et al [129]. 
Plasminogen activator inhibitor 1 (PAI-1) functions as an inhibitor of t-PA and plays an 
important role in thrombolysis, which is the crucial part of venous recanalization [139]. 
Subjects with an increased PAI-1 activity have an increased risk for slow recanalization and 
remaining thrombus in the chronic phase of DVT [140]. The study of Obi et al. found that low-
molecular weight heparins reduce the activity of PAI-1, which might be one of the 
mechanisms of its anticoagulation effect [141]. Although lower PAI-1 activity improves 
thrombus degradation, several studies show increased venous wall fibrosis in patients with 
less active PAI-1 [142]. Our study also found an association between levels of PAI-1 and DVT. 
We found higher PAI-1 levels in DVT patients in comparison to the control group, which might 
indicate that increased PAI-1 is a predisposition for a less efficient thrombolysis, which can 
increase the risk for a symptomatic DVT. This was also indicated by the study of Bern et al., 
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which showed decreased fibrinolysis in patients with increased PAI-1 levels [143].  No studies 
found an association between PAI-1 and PTS [144]; we also found no differences in PAI-1 
levels between our PTS-positive and PTS-negative patients.  
Contrary to some other studies we found no differences in serum markers between PTS-
positive and PTS-negative patients. This can be due to a relatively small sample in which 
smaller differences cannot be statistically significant. Important was also the fact that the 
blood was collected between 12 and 36 months after the acute DVT. As other studies that 
found some differences in levels of serum markers between PTS-positive and PTS-patients 
analysed blood samples collected shortly after acute DVT, it is possible that serum marker 
levels in the early aftermath of acute DVT are associated with development of PTS later in the 
course of the disease, while in the chronic phase the effect of DVT on levels of serum markers 
is diminished and harder to measure. Our aim was to find differences in the levels of serum 
markers between patients with an already developed PTS and PTS-negative patients, which 
we could not prove, however, this does not mean that levels of inflammatory and fibrinolytic 
markers in the acute phase of DVT could not be important for a later development of PTS. It 
is also possible that levels of serum markers do not have a significant role in PTS and that 
other factors are more important. 
On the other hand, we found important differences between DVT patients and the control 
group, while DVT was in the chronic, not acute phase. Higher levels of CRP and leukocytes 
among DVT patients indicate a more expressed inflammatory activity in comparison to 
subjects without a history of DVT even years after the acute event, which is in line with results 
of some other studies [120]. Higher values of inflammatory markers might be a consequence 
of DVT. However, another possibility is that patients who develop DVT might have a more 
expressed pro-inflammatory potential before DVT, which could be one of the reasons for DVT 
in patients without a clear risk factor.  
We found differences between DVT patients and the control group also in the levels of 
fibrinolytic markers; statistically significant differences in all three markers included in the 
study (D-dimer, t-PA and PAI-1) were found. Process of fibrinolysis is important in the 
pathophysiology of DVT in its acute and chronic phase. While t-PA triggers the thrombolysis, 
D-dimer is a product of this process. As thrombolysis takes place after DVT, it is expected that 
these two markers are increased after acute DVT. We found that they are increased even 1 
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to 3 years after the acute event, indicating DVT is a chronic process which has an effect on 
the human physiology for a long period of time. On the other hand, PAI-1 is an inhibitor of t-
PA, therefore, increased levels of both in DVT patients seem somewhat contradictory. 
However, we measured total PAI-1, not PAI-1 activity. It could mean that people who develop 
DVT might have genetically higher levels of PAI-1 already before DVT occurs, and as their 
thrombolysis is more inhibited by higher PAI-1 levels, the incidence of symptomatic DVT is 
increased. It is also possible that as a consequence of DVT, all factors that have a role in 
thrombolysis are more expressed, both profibrinolytic and antifibrinolytic.  
The results of the study indicate that DVT is a chronic process, as both inflammatory and 
fibrinolytic activity seem to be more expressed even several years after the acute event, when 
compared to the general population. However, in patients with an already developed PTS, 
levels of inflammatory and fibrinolytic markers do not seem to be increased in comparison to 




DVT is a relatively common disease, while PTS is its most frequent chronic complication, which 
can significantly affect the quality of life. Pathophysiology of PTS is partially understood, 
however, a lot is still unknown. Our study focused on different factors that might be related 
to the PTS. The main findings are the following:  
 
- PTS occurs in about 34% of our DVT patients, more commonly among older patients 
and patients with recurrent DVT. The most common symptoms and signs are leg 
swelling, venous ectasia, leg pain, and leg heaviness. Patients with PTS have a reduced 
function of the lower limbs. Care for PTS prevention and symptom reduction is 
necessary in DVT treatment.  
 
- Patients who develop PTS more often have a remaining thrombus in the affected vein 
years after the acute DVT and a lower rate of venous recanalization in comparison to 
the DVT patients who do not develop PTS. Efficient recanalization is probably 
important in DVT treatment. 
 
- DVT patients treated with rivaroxaban had lower incidence of PTS in comparison to 
patients treated with warfarin. Larger randomized study would be needed for stronger 
evidence. Almost all DVT patients daily used compression therapy at least in the initial 
period after the acute DVT.  
 
- Patients with DVT had increased diameter of the brachial artery, more deteriorated 
endothelial function of the brachial artery and more expressed arterial stiffness in 
comparison to the control group, which indicates that there probably is an association 
between venous disease and arterial wall function. We found no differences in the 
properties of the arterial wall between PTS-positive and PTS-negative patients.  
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- DVT patients have higher levels of CRP, leukocytes, t-PA, PAI-1, and D-dimer in 
comparison to the control group, which indicates an increased inflammatory and 
fibrinolytic activity in DVT patients even years after the acute DVT. We found no 
differences in levels of serum markers between PTS-positive and PTS-negative 
patients. 
 
In conclusion, we found deteriorated function of the vessel wall and increased levels of the 
systemic inflammatory markers in DVT patients in comparison to the control group; therefore, 
our first hypothesis was confirmed.  
We found no differences in the vessel wall function and levels of systemic inflammatory 
markers between PTS-positive and PTS-negative patients; therefore, our second hypothesis 
was not confirmed.  
Additionally, we investigated the incidence and forms of PTS among our patients, found lower 
recanalization rate of the affected veins in PTS patients, observed lower incidence of PTS in 
the patients treated with rivaroxaban in comparison to warfarin and measured increased 
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